Post on 24-Apr-2023
This chapter was originally published in the book Advances in Clinical Chemistry, Vol. 68 published by
Elsevier, and the attached copy is provided by Elsevier for the author's benefit and for the benefit of the
author's institution, for non-commercial research and educational use including without limitation use in
instruction at your institution, sending it to specific colleagues who know you, and providing a copy to
your institution’s administrator.
All other uses, reproduction and distribution, including without limitation commercial reprints, selling or
licensing copies or access, or posting on open internet sites, your personal or institution’s website or
repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier's
permissions site at:
http://www.elsevier.com/locate/permissionusematerial
From Guilherme Bresciani, Ivana Beatrice Mânica da Cruz and Javier González-Gallego, Manganese
Superoxide Dismutase and Oxidative Stress Modulation. In: Gregory S. Makowski, editor, Advances in
Clinical Chemistry, Vol. 68, Burlington: Academic Press, 2015, pp. 87-130.
ISBN: 978-0-12-802266-5
© Copyright 2015 Elsevier Inc.
Academic Press
Provided for non-commercial research and educational use only. Not for reproduction, distribution or commercial use.
CHAPTER FOUR
Manganese SuperoxideDismutase and Oxidative StressModulationGuilherme Bresciani*,1, Ivana Beatrice Manica da Cruz†,Javier González-Gallego{*Facultad de Ciencias de la Salud, Universidad Autonoma de Chile, Temuco, Chile†Laboratorio de Biogenomica, Departamento de Morfologia, Universidade Federal de Santa Maria,Santa Maria, Brazil{Institute of Biomedicine (IBIOMED) and Centro de Investigacion Biomedica en Red de EnfermedadesHepaticas y Digestivas (CIBERehd), University of Leon, Leon, Spain1Corresponding author: e-mail address: guilhermebresciani@gmail.com
Contents
1. Introduction 892. Oxidative Stress: A Brief Review 91
2.1 Mitochondrial role in energy production 912.2 ROS generation and effects in the organism 92
3. Superoxide Dismutase in Antioxidant Defense 963.1 Antioxidant defense 963.2 Superoxide dismutase 97
4. MnSOD and Oxidative Stress Modulation 994.1 Nervous system 1004.2 Metabolic-related conditions 1054.3 Cardiovascular system 108
5. Environmental Factors, Genetics, and MnSOD Modulation 1115.1 Exercise, oxidative stress, and health: Evidence for MnSOD involvement 111
6. Conclusions 113Acknowledgments 114References 114
Abstract
Oxidative stress is characterized by imbalanced reactive oxygen species (ROS) produc-tion and antioxidant defenses. Two main antioxidant systems exist. The nonenzymaticsystem relies on molecules to directly quench ROS and the enzymatic system is com-posed of specific enzymes that detoxify ROS. Among the latter, the superoxide dis-mutase (SOD) family is important in oxidative stress modulation. Of these,manganese-dependent SOD (MnSOD) plays a major role due to its mitochondrial loca-tion, i.e., the main site of superoxide (O2
•�) production. As such, extensive research has
Advances in Clinical Chemistry, Volume 68 # 2015 Elsevier Inc.ISSN 0065-2423 All rights reserved.http://dx.doi.org/10.1016/bs.acc.2014.11.001
87
Author's personal copy
focused on its capacity to modulate oxidative stress. Early data demonstrated the rel-evance of MnSOD as an O2
•� scavenger. More recent research has, however, identifieda prominent role for MnSOD in carcinogenesis. In addition, SOD downregulationappears associated with health risk in heart and brain. A single nucleotide polymor-phism which alters the mitochondria signaling sequence for the cytosolic MnSOD formhas been identified. Transport into the mitochondria was differentially affected by allelicpresence and a new chapter in MnSOD research thus begun. As a result, an ever-increasing number of diseases appear associated with this allelic variation includingmetabolic and cardiovascular disease. Although diet and exercise upregulate MnSOD,the relationship between environmental and genetic factors remains unclear.
ABBREVIATIONSAD Alzheimer’s disease
AIF apoptosis-inducing factor
Ala alanine
ATP adenosine triphosphate
BD bipolar I disorder
CADs cardiovascular diseases
CAT catalase
CNS central nervous system
Cu/ZnSOD cytosolic copper–zinc-dependent superoxide dismutase
Cyt c cytochrome c
DNA deoxyribonucleic acid
ETC electron transport chain
ecSOD extracellular superoxide dismutase
FEP first episode psychosis
GPx glutathione peroxidase
GSH glutathione
HCC hepatocellular carcinoma
HCV hepatitis C virus
HHC hereditary hemochromatosis
HDL high-density lipoprotein
LDL low-density lipoprotein
MDA malondialdehyde
MDD major depressive disorder
MnSOD manganese-dependent superoxide dismutase
mRNA messenger ribonucleic acid
mtDNA mitochondrial deoxyribonucleic acid
ox-LDL oxidized low-density lipoprotein
PD Parkinson’s disease
rDD recurrent depressive disorder
RNA ribonucleic acid
ROS reactive oxygen species
SNP single nucleotide polymorphism
88 Guilherme Bresciani et al.
Author's personal copy
SOD superoxide dismutase
TD tardive dyskinesia
Val valine
8-OhdG 8-hydroxy-2’deoxyguanosine
α alpha
β beta
1. INTRODUCTION
During the last few decades, researchers in biochemistry, biology,
chemistry, and physiology have studied the self-regulating modulation of
the bioenergetics of aerobes, i.e., “oxidative stress.” The growing interest
in this phenomenon is due to the peculiar characteristics presented by oxi-
dative stress that change the way we perceive this vital molecule, oxygen
(O2). O2 is essential for aerobic survival in our oxygen-rich atmosphere
has played a major role in aerobic evolution due to its unique properties
as the final electron acceptor of the mitochondrial electron transport chain
(ETC) [1]. Without O2, organisms would have been unable to evolve into
more complex multicellular life forms. Bioenergetics would be decreased
and less effective, thus directly affecting reproduction and dampening prop-
agation of varieties and species.
Nevertheless, O2 metabolism also presented aerobes with a challenge. It
is well known that more than 90% of the body’s O2 is consumed by the ETC
in mitochondria [2]. O2 reduction is, however, complex, i.e., the molecule
has two parallel spinning unpaired electrons in its outermost orbital [3].
According to Pauli’s Exclusion Principle, it is impossible to reduce O2 in
one step. Consequently, it undergoes a one-electron reduction to produce
the first free radical found in aerobes, the superoxide anion (O2•�) [4]. Inter-
mediates in the O2 reduction process are called free radicals—molecules that
contain an unpaired electron (radical) and are capable of independent exis-
tence (free) [3]. Free radicals derived from O2 metabolism are also known as
reactive oxygen species (ROS) [5].
The relevance of the ROS relies on their dual role in aerobes (Fig. 1).
At physiologic concentration, ROS have been implicated in modulation
of gene expression and cellular signaling [6]. First recognized as toxic metab-
olites of O2 metabolism, ROS are now known to be significant modulators
of different signaling pathways [7,8]. In addition, they play a key role in
89Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
inflammation via adhesion and chemotaxic molecules. Uncontrolled ROS
release, however, leads to oxidation of cellular components, such as proteins,
lipids, and deoxyribonucleic acid (DNA). As such, uncontrolled ROS pro-
duction by oxidative metabolism and other sources may cause distress lead-
ing to cellular damage [9]. Therefore, ROS are linked to physiologic and
pathophysiologic conditions depending on the balance of production and
clearance. Equilibrium between oxidants and antioxidants is required to
reach homeostasis. Oxidative imbalance may result in pathologic response
and lead to important functional disruptions and associated diseases.
Over the last few decades, oxidative stress and its role in pathology have
been extensively studied. A fewROS-relatedmolecular pathways have been
identified and subsequently linked to metabolic-related diseases. Harman
was the first scientist to propose a link between free radicals and deleterious
effects to the organism, stating that aging was a process that was at least in part
caused by free radicals [10]. Among the most studied and well-described
oxidative stress-related diseases are cardiovascular diseases (CADs) [11],
metabolic-related [12], and neurodegenerative conditions [13]. Neverthe-
less, the exact role of oxidative stress as a disease cause or consequence
has yet to be fully clarified. Epidemiologic and associative studies established
a potential relationship between genetics and diseases in the early 1990s.
Research has evaluated the effects of genes and single nucleotide polymor-
phisms (SNPs) on the expression of proteins’ key to oxidative stress control,
i.e., antioxidant enzymes. Therefore, elucidation of the molecular biology
and the genetics of key antioxidant proteins have achieved more promi-
nence in recent years.
Figure 1 Reactive oxygen species (ROS)-mediated actions in the organism. The mito-chondrial electron transport chain (ETC) ROS production is related to bothphysiological- and pathological-related mechanisms.
90 Guilherme Bresciani et al.
Author's personal copy
2. OXIDATIVE STRESS: A BRIEF REVIEW
The O2 molecule was introduced into earth’s atmosphere approxi-
mately 2–3 billion years ago due to the evolution of O2-releasing photo-
synthetic organisms. Current levels (�21%) were reached within a few
million years. This O2-loaded environment applied selective pressure to
living organisms and ultimately led to propagation of aerobes. The great
advantage provided by oxidative metabolism relied on complete combus-
tion of glucose [14]. O2 oxidized biologic substrates to supply energy for
aerobic survival [15] and played a key role as an electron acceptor in the
ETC [16]. This process is not a single-step reaction, but an electron transfer
sequence mediated through enzymatic systems that lead to the final elec-
tron acceptor.
In 1954, Commoner and coworkers identified free radicals in biologic
tissues [17]. Denham Harman then hypothesized that O2 radicals were
produced as byproducts of enzyme activities in vivo [10]. Free radicals were
described as a “Pandora’s box” due to their potential involvement in cell
damage, mutagenesis, cancer, and the degenerative process of aging. As
such, excessive ROS production likely triggers cellular/tissue damage the
extent of which is related to cellular redox state. Cells are able to maintain
a redox state when low or moderate levels of ROS are produced, whereas
increased ROS overwhelm antioxidant defense leading to oxidative stress
and cellular damage [18]. Redox state disruption may cause toxicity via pro-
duction of peroxides and free radicals and some irreversible damage may
occur. The mitochondrion is one of the main intracellular sites for ROS
production [19,20]. From this point, cellular damage accumulates ultimately
degrading the physiologic capacities of various systems, and leading to CADs
[21,22], metabolic-related conditions [23,24], and neurodegenerative disor-
ders [25,26].
2.1. Mitochondrial role in energy productionMitochondria are ubiquitous organelles that perform crucial cellular func-
tions in eukaryotes and, as such, have been considered “gatekeepers of life
and death” [27]. Major mitochondrial processes include the production of
over 90% of cellular adenosine triphosphate (ATP), regulation of intracel-
lular calcium (Ca2+), redox signaling, and modulation of apoptosis
[28,29]. The majority of biochemical energy required for cell function is
produced in the mitochondria. Energy generation occurs through ATP
91Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
turnover during oxidative phosphorylation in the ETCwith O2 as substrate.
This metabolic reaction takes place in the mitochondrial inner membrane
and is driven by the release of a proton gradient generated by the pumping
of hydrogen (H+) into the intermembrane space by metabolic reactions via
cytochromes. Electrons released through the metabolism of carbohydrate
and fatty acid metabolism are captured by nicotine adenine dinucleotide
(NAD) and flavin adenine dinucleotide (FAD) systems, that act as electron
carriers in the ETC. Electron transport into the mitochondria generates an
electrochemical gradient across the inner mitochondrial membrane.
Decreased ATP concentration triggers proton transfer through ATP
synthase into the mitochondrial matrix and this energy is captured to gen-
erate ATP [30].
During this process, however, 2–5% of O2 undergoes univalent reduc-
tion generating O2•�[31], the first ROS produced by this pathway [32]. As
such, ROS are atoms or molecules with one unpaired electron in their out-
ermost shell which renders them highly reactive and unstable [3,32]. This
species reacts with other atoms or molecules via oxidation–reduction that,
in turn, activate a cascade of ROS production. Thus, formation of O2•� dur-
ing cell respiration can give rise to other ROS.
2.2. ROS generation and effects in the organismROS can be produced by other processes including catecholamine auto-
oxidation, immune system cell activation, ischemia, and/or hypoxia–
reperfusion damage [31]. ROS can also be generated by estrogens and their
metabolites, by a variety of xenobiotics and by the xanthine–xanthine oxi-
dase system [15]. Despite these ancillary sources, mitochondrial O2•�-
mediated ROS represents the most relevant cascade of production
(Fig. 2). Hydrogen peroxide (H2O2) is synthesized by bivalent reduction
of O2 with the addition of two protons (H+). It is noteworthy that dis-
mutation of O2•� can also produce H2O2[14]. Reaction of free iron
(Fe2+) and H2O2 generates hydroxyl radical (OH•), which appears respon-
sible for lipid, protein, and DNA damage [34]. OH• is very reactive and
toxic, and there is no specific antioxidant enzyme against this ROS [35].
Hypochlorous acid is generated via action of myeloperoxidase on H2O2.
Although this strong oxidant is important for destruction-ingested microor-
ganisms, it can also harm neighboring tissues via oxidation of thiols, lipids,
and ascorbate [34]. O2•� dismutation can also produce singlet oxygen (1O2),
92 Guilherme Bresciani et al.
Author's personal copy
Figure 2 Reactive oxygen production (ROS) in the mitochondria and cytosol. NADHcollects electrons from the oxygen molecules (O2). The electrons subsequently flowthrough the mitochondrial electron transport chain (ETC) complexes for ATPresynthesis. A small amount of the O2 undergoes an incomplete reduction giving riseto the superoxide anion (O2
•�), the first ROS within the aerobic organisms. After, themanganese-dependent superoxide dismutase (MnSOD) dismutates the O2
•� intohydrogen peroxide (H2O2) and O2; the H2O2 is further neutralized by the glutathioneperoxidase (GPx) into H2O with glutathione (GSH) as a substrate. Equally, H2O2 maybe also converted into the hazardous hydroxyl radical (OH•) through Fenton reactionwith iron (Fe2+). Outside the mitochondria, the O2 can also be converted into O2
•�
through an NADPH-oxidase reaction with nicotinamide adenine dinucleotide phos-phate (NADPH) as substrate. Further, the copper–zinc-dependent superoxide dismutase(Cu/ZnSOD) dismutates the O2
•� in the membrane interspace while the same reactiontakes place in the extracellular milieu by the extracellular superoxide dismutase(ecSOD). Here, the H2O2 is also neutralized by the GPx, although catalase (CAT) alsoreacts with this ROS. The O2 molecule may also give rise to the nitric oxide (NO•) acrossa nitric oxide synthase (NO synthase) reaction using arginine as a substrate. The NO•
may also react with the O2•� to form the highly reactive peroxynitrite anion
(ONOO�). Adapted from Ref. [33].
93Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
which has no unpaired electrons but has strong oxidizing ability [34]. Per-
oxynitrite (ONOO�), a reaction product of NO• and O2•�, is a potent and
versatile oxidant that attacks a wide range of biologic molecules causing thiol
depletion, DNA damage and protein nitration [36]. This process is widely
believed to represent a major pathway for reactive nitrogen species (RNS)
generation [14,37]. Therefore, ROS imbalance can also result in nitrosative
stress, which has been implicated in a variety of disorders including neuro-
vascular pathogenic cascades [38], CADs [39], and diabetes [40]. Although
O2•� and NO• have relevant physiologic roles at low concentration,
increased ROS is harmful [41–44]. Elucidation of ROS mechanisms of
action will improve our understanding of the fundamental processes
involved with disease biology and pathophysiology.
2.2.1 Lipid peroxidationLipid peroxidation is a physiologic process primarily affecting cell mem-
branes. Peroxidation of polyunsaturated fatty acids occurs as a consequence
of double bond weakening, production of conjugated dienes, O2 addition,
peroxy radical formation, and H+ loss from lipid. Because cells do not have
mechanisms to dispose of these byproducts, lipid peroxidation is considered
irreversible [45]. This phenomenon may lead to accumulated cell damage
classified as (1) changes to membrane-associated enzymes, ionic channels
or receptors that activate or inactivate them [46], (2) the opening of new
channels of cell permeability [47], (3) the formation of cross-linked proteins
(irreversible inactivation) [48], and (4) sulfhydryl group oxidation at the
active sites of membrane-bound enzymes [49]. Additionally, based on the
magnitude of ROS damage, losses in cell membrane fluidity and secretory
functions may also be observed. Damage to specific organelles, i.e., lyso-
somes, may result in the release of phospholipases and other enzymes that
promote additional membrane degradation [50]. Increased membrane per-
meability results in facilitated ion influx that activates phospholipases, thus
promoting additional permeability [51].
2.2.2 Protein and enzyme oxidation and glycosylationROS interaction with enzymes and other proteins (structural, receptors, and
transporters) can induce the oxidation of sulfhydryl groups, methionine, and
amino acids [52]. Introduction of carbonyl groups affects both the structure
and activity of these proteins [53]. Some of these groups are easily oxidized
and the damage, similar to that in lipid, is irreversible. As such, protein car-
bonylation is considered an irreversible posttranslational modification [54].
94 Guilherme Bresciani et al.
Author's personal copy
ROS may induce protein cross-linking, aggregation, and denaturation,
causing a cascade of damage [55]. Protease inhibitors can also become inac-
tive, inducing relevant physiologic alterations. Damage to channel proteins
can lead to disrupted cell function due to ion imbalance [56].
2.2.3 Metabolic disruptionMitochondrial ETC complexes I and III are the primary sites of ROS pro-
duction and release [21,27]. Complex III produces O2•� by autooxidation of
the ubisemiquinone radical intermediate (QH•). The Qo site is the major
O2•� producer in the inner membrane. The complex III Qi site is closer
to the matrix side and is less likely to react with oxygen and form O2•�,
i.e., this site firmly binds QH• and stabilizes it in the matrix [21]. Complex
III has the capacity to release O2•� to both sides of the mitochondrial inner
membrane depending on which portion of the Q cycle is involved [57]. The
precise mechanisms of complex I O2•� generation are largely unknown.
However, it has been suggested that complex I produces O2•� by reverse
electron transfer from complex II during succinate oxidation in the absence
of NADH-linked substrates. Alternatively, much lower amounts may be
generated by forward electron transfer from the NADH-linked substrates.
Interestingly, the latter mechanism may account for more of the physiolog-
ically relevant ROS produced in the mitochondria [58,59]. The NADH
coenzyme transports a large quantity of chemical energy in reduced form
and O2•� electron capture interferes with the NADH oxidation to
NAD+ thus affecting metabolic roles of NADH in antioxidant defense
and ATP turnover [60]. Therefore, the effects of ROS on energy transport
molecules greatly control energy production and use.
2.2.4 Oxidation of nuclear and mitochondrial nucleic acidsWhen antioxidant defenses are overwhelmed, DNA can suffer direct ROS-
mediated damage through H2O2 and OH•. Nucleotide modification and
DNA rupture are the major consequences of this damage [61], including
single- and double-stranded breaks, DNA–DNA and DNA–protein
cross-links, and base modifications [62]. Although repairable, multiple
ROS-mediated lesions in proximal nucleotides (tandem lesions) overwhelm
DNA repair mechanisms and induce deleterious genetic change over
time [63].
ROS damage is also a challenge to mitochondrial DNA (mtDNA). The
mitochondrion has its own DNA which codes for specific ribonucleic acids
(RNAs) necessary for homeostasis. Studies have demonstrated that mtDNA
95Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
is also susceptible to ROS-mediated damage [64–66]. In fact, mtDNA is
more sensitive than nuclear DNA to ROS damage due to its lack of repair
processes. As can be expected, accumulation of oxidative damage within
mitochondria and mtDNA likely increases mutation rates, leading to
decreased bioenergetic function and increased cell dysfunction [62,63].
3. SUPEROXIDE DISMUTASE IN ANTIOXIDANT DEFENSE
3.1. Antioxidant defenseOrganisms use nonenzymatic and enzymatic antioxidant systems to protect
against ROS and subsequent damage to membranes and macromolecules.
These important systems are responsible for homeostasis and genomic integ-
rity. The nonenzymatic system is composed of a myriad of antioxidant mol-
ecules such as retinol, ascorbic acid, tocopherol, flavonoids, thiols, uric acid,
ferritin, bilirubin, and a few micronutrients [67]. The antioxidant molecules
directly quench ROS thus preventing oxidative damage [35].
Main antioxidant enzymes are superoxide dismutase (SOD, EC 1.15.1.1,
superoxide:superoxide oxidoreductase), glutathione peroxidase (GPx, EC
1.11.1.9, glutathione:hydrogen peroxide oxidoreductase), and catalase
(CAT, EC 1.11.1.6, hydrogen peroxide:hydrogen peroxide oxidoreduc-
tase) [68]. These enzymes are compartment specific and regulated geneti-
cally [69]. SOD dismutates O2•� into H2O2 to avoid accumulation to
toxic level [70]. The primary mechanism to eliminate H2O2 and lipid per-
oxides in the cytosol and mitochondria is catalyzed by GPx, which uses glu-
tathione (GSH) to reduce H2O2 and hydroperoxides into water and
alcohols, respectively [71]. CAT is one of the most abundant peroxisomal
proteins in mammalian cells and converts H2O2 into H2O and O2[72]
(Fig. 2).
GPx, located in the cytosol and mitochondria, detoxifies H2O2 and
hydroperoxides (ROOH) into H2O and alcohols (ROH), respectively
[35,71]. Different GPx isoforms have been identified in mammals [73].
Although sharing the ability to reduceH2O2, isoforms differ in tissue expres-
sion and substrate requirement [74]. This unique characteristic optimizes
their antioxidant role [71]. CAT is a homotetramer with a molecular weight
of 240 kDa [75]. Although its primary role is to catalyze the hydrolysis of
H2O2 into H2O and O2, the enzyme has been implicated in several bio-
chemical pathways. Despite its ubiquitous distribution, CAT is primarily
localized in peroxisomeswhich useO2•� to detoxify organic byproducts [76]
and produce H2O2. Although CAT performs the same catalytic reaction as
96 Guilherme Bresciani et al.
Author's personal copy
GPx, it has higher affinity for H2O2[71]. As such, CAT may represent an
important protective mechanism against increased H2O2 concentration
due to its higher Km.
3.2. Superoxide dismutaseSOD is the first line of defense in the antioxidant enzyme repertoire, cata-
lyzing O2•� anion dismutation into O2 and H2O2. This remarkable discov-
ery was first reported by McCord and Fridovich in the late 1960s. This
finding suggested that the copper-based protein described by Mann and
Keilin could catalyze Pauling free radical (O2•�) reduction [69]. Its final
product, H2O2, is less reactive and generation of highly reactive OH• radical
is avoided.
Three isoforms of SOD have been described in humans. These include
the cytosolic copper–zinc-dependent form (CuZnSOD, SOD1), the mito-
chondrial manganese-dependent form (manganese-dependent SOD
[MnSOD], SOD2), and the extracellular copper–zinc-dependent form
(extracellular SOD [ecSOD], SOD3). It is noteworthy that each isoform
requires a redox transition metal in its active site to dismutate O2•�. This
finding may, in fact, partially explain the enormous relevance of dietary
micronutrients [77]. SOD1 requires copper and zinc as cofactors and is
located in the cytosol, nucleus, peroxisomes, and intermembrane space of
the mitochondria [78]. This isoform is essential for antioxidant defense
and mutations of this enzyme have been linked to neurodegenerative disor-
ders such as amyotrophic lateral sclerosis [79,80]. The ecSOD isoform also
requires copper and zinc as cofactors for redox activity maintenance. The
ecSOD isoform is produced by smooth muscle cells and released [81].
Due to its extracellular location, ecSOD has been hailed as the principal
regulator of endothelium-derived NO• bioactivity through its O2•�-
scavenging activity [77,82]. ecSOD is present in blood vessels, heart, lungs,
bladder, and extracellular fluids [78]. It has been suggested that ecSOD plays
an important role in neurologic and cardiovascular disorders [78,81].
Unlike Cu/Zn-dependent SODs, mitochondrial SOD requires manga-
nese as a cofactor. MnSOD, the only isoform present in mitochondria, is
considered essential for aerobic survival [83,84]. Genetic studies have rev-
ealed that the null homozygous mutation (MnSOD�/�) is lethal, whereasknockouts of Cu/ZnSOD and GPx are not [85]. MnSOD-knockout
mice have severe mitochondrial damage, decreased GSH, increased 8-
hydroxy-20deoxyguanosine (8-OhdG), and diminished respiratory control
97Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
[86,87]. These animals do not survive to adulthood and die shortly after
birth. Heterozygous MnSOD-knockout mice with 50% enzyme activity
also show increased 8-OhdG DNA damage in nuclear and mtDNA versus
wild-type controls [88]. The short lifespan in MnSOD knockouts is likely
related to the enzyme’s role in maintaining nanomolar or lower O2•�
concentration [89].
Antioxidant activity of the aforementioned enzymes may be affected by
several factors. Nature and nurture both play roles in antioxidant modulation
in aerobes. Diet, alcohol consumption, and physical activity may induce rel-
evant changes at the molecular level, especially in humans. Increased under-
standing of the role of the environment in the molecular biology of
organisms will be discussed below.
3.2.1 MnSOD and the Ala16ValSNPThe SNP is the most common genetic mutation and occurs at a frequency of
�1% in humans [90]. SNP has important roles in biosciences and serves as
genetic markers of different diseases [91] and is responsible for �90% of
all human genetic variation [92]. The SNP is characterized by a single base
change or deletion within a gene that can potentially lead to amino acid
modification in specific proteins to influence phenotypic alteration [93].
While “silent” SNP is benign, others may alter protein structure and func-
tion [94]. It is estimated that an average of one SNP occurs for every
1000–2000 nucleotide bases; depending on the DNA region, this ratio
may reach one in 300 [91,95]. As can be expected, variation in DNA
sequence may lead to altered immune mechanisms in response to disease,
bacteria, virus, and xenobiotic exposure [91]. In fact, SNPs have been
described for the most genes encoding the main antioxidant enzymes.
The SNP in the GPx1 gene (Pro198Leu, rs1050450) has been identified
in erythrocytes and several epithelial tissues including breast [96]. The
CAT C262T (rs1001179) SNP alters the transcription factor binding and
basal CAT activity in red blood cells [97]. More than 190 SNPs have been
detected for MnSOD, which may explain its relevance as a first line of anti-
oxidant defense to ROS [93,98]. The main SNPs described so far for the
MnSOD are Ile58Thr (rs1141718) and Ala16Val (rs4880) for MnSOD.
Substitution of isoleucine (Ile) for threonine (Thr) at amino acid position
58 has been linked to tumor suppression in human breast cancer cells [99].
The most studied SNP, Ala16Val, results from the substitution of cytosine
for thymine in exon 2. At the protein level, this genetic change results in
substitution of valine (Val) for alanine (Ala) in codon 16 [100]. The single
98 Guilherme Bresciani et al.
Author's personal copy
amino acid substitution results in a distinct conformational change (β [beta]-sheet to α [alpha]-helix) in this region which modifies the mitochondrial
import ofMTS-MnSOD.While the majority of the Val variant is embedded
within the mitochondrial inner membrane, the Ala variant easily crosses
both mitochondrial membranes to reach the matrix (Fig. 3) [102]. Previous
studies have found a more active (30–40%), matrix-localized and processed
MnSOD homotetramer for the Ala–MnSOD precursor [103].
4. MnSOD AND OXIDATIVE STRESS MODULATION
Consistent with its role in ROS detoxification via O2•� dismutation,
MnSOD is important in a number of physiologic systems. MnSOD
upregulation was shown to mitigate apoptosis in brain [104], diabetic cardi-
opathy [105], cell signaling death in liver [106], and restored redox balance
in the skeletal muscle following exercise [107]. ROS are frequently associ-
ated with pathophysiology and an increasing number of diseases are associ-
ated with ROS activity as an etiologic agent or contributing factor [108].
Several studies have shown that MnSOD induction can protect against
Figure 3 Manganese-dependent superoxide dismutase (MnSOD) content in the mito-chondria according to different Ala16Val precursors. While the alanine (Ala) precursor iscorrectly transported across both mitochondrial membranes (MTS-Ala), the valine (Val)precursor is partially arrested in the inner membrane (MTS-Val). The increased MnSODcontent afforded by the Ala precursor is translated into a more efficient superoxide(O2
•�) detoxification, whereas the Val precursor leads to O2•� accumulation in the mito-
chondria. Adapted from Ref. [101].
99Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
neurotoxic conditions [102], cardiomyopathy [105,109], and diabetic disor-
ders [110,111]. Environmental and/or genetic factors that modulate antiox-
idant response to different stimuli have been described. The relationship
between the mutation of genes encoding antioxidant enzymes and oxidative
stress-related diseases has generated growing interest in how these SNPs
might be useful in understanding disease-related pathways [101]. An increas-
ing number of studies have investigated the relationship of the Ala16Val
SNP with neural, metabolic, and CAD.
4.1. Nervous systemAlthough the brain represents only 2% human body weight, 15% of cardiac
output, and 20% of total body O2 consumption are driven by this organ
[112,113]. This increased metabolism is largely due to neuronal energy
demand for maintaining ion gradients across the plasma membrane which
is critical to action potentials [112]. As such, the brain is especially prone
to ROS-mediated damage due to increased O2 consumption, polyunsatu-
rated fatty acids and transition metals, and reduced antioxidant defenses [25].
The balance between O2•� and H2O2 production/catalysis represents a
crucial component of cell metabolism. In addition, these molecules are
highly relevant to signaling pathways that respond to a wide range of phys-
iologic conditions. O2•� and H2O2 production/catalysis is particularly
important to the central nervous system (CNS) and peripheral nervous sys-
tem (PNS), given cyto-anatomic and functional nature of neuronal cells. In
general, neurons are highly complex cells with extremely long processes,
i.e., axons may extend up to 1 m in motor neurons. This structure is impor-
tant to guarantee the major neural function of communication with other
body cells and tissues [114].
Neuronal architecture requires highly organized organellar transport,
especially for mitochondria, which produces metabolic energy. Regulation
of mitochondrial activity is particularly important in brain, an organ highly
dependent on oxidative phosphorylation for ATP. High ATP demand
results in significant ROS production primarily controlled by antioxidant
enzymes thus avoiding oxidative stress. Neuronal oxidative stress has been
linked to apoptosis and implicated in neurodegenerative diseases [26].
SOD imbalance appears related to several neurodegenerative conditions
due to O2•�-mediated damage to ETC components and other cellular con-
stituents [115]. Excessive ROS, generated from mitochondrial dysfunction,
accumulation of transition metals or β-amyloid peptide and tau proteins
100 Guilherme Bresciani et al.
Author's personal copy
(proteins that stabilize microtubules), promote redox imbalance [116].
Despite the apparent role of oxidative stress in Alzheimer’s disease (AD),
clinical management failed to demonstrate clear benefit of antioxidant ther-
apy [117]. Significant heterogeneity in research design, differential control
of confounders, insufficient measures of cognitive performance, and diffi-
culty with dietary assessment likely contributed to poor study outcome
[118]. Despite these findings, imbalance associated with antioxidant enzyme
deregulation may be core to AD initiation and progression. This hypothesis
is corroborated by investigations that have shown an antioxidant enzyme
imbalance associated with AD primarily involving MnSOD. Previous clin-
ical findings have reported upregulation of antioxidant enzymes, i.e.,
MnSOD, in disease progression [119]. In fact, Swomley et al. [120]
described alterated blood antioxidant markers in AD, including increased
erythrocyte Cu/ZnSOD and upregulated lymphocyte MnSOD messenger
RNA (mRNA).
There are several explanations for increased MnSOD in AD. MnSOD
upregulation is a potential compensatory mechanism against elevated
oxidative stress found in neural cells undergoing AD alteration. Increased
mitochondrial O2•� could trigger a concomitant increase in MnSOD.
The O2•� anion production via NADPH-oxidase (NOX) plays a role in
a variety of neurological diseases, including AD [121]. Guix et al. [122] dem-
onstrated increased ONOO� (via O2•�–NO• reaction) using an in vitro
model of neuronal aging during their investigation of inherited familial
AD. Increased MnSOD can also increase H2O2 and contribute to oxidative
stress and AD pathogenesis. H2O2 is a known stimulator of β-amyloid secre-
tion. β-Amyloid is a metal-binding protein and copper, zinc, and iron pro-
mote oligomer formation. In rat brain, decreased MnSOD triggered
increased β-amyloid deposition in the parenchyma and increased amyloid-
osis in the vasculature. It is likely thatMnSOD imbalance has a central role in
AD pathogenesis (Fig. 4).
It should be noted that copper and iron are redox active and can generate
ROS via the Fenton reaction, a chemical reaction between H2O2 and tran-
sition metals, and the Haber–Weiss reaction [123]. Increased oxidative stress
in AD is correlated to increased iron, copper, protein, andDNAoxidation and
enhanced lipid peroxidation in the brain [124]. Neurodegeneration has been
speculated to result from the interplay between environmental and genetic
factors. ROS-related neurodegeneration appears associated with certain
genetic mutations that create susceptibility to neurologic pathology [113].
101Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
Genetic SNP affecting MnSOD efficiency could help us understand the
relevance of this antioxidant enzyme imbalance in AD. Wiener et al. [125]
investigated the potential association between four SNPs and AD. This study
corroborated the relevance of MnSOD imbalance in AD. The results were
obtained using family-based association testing results in the National Insti-
tute of Mental Health-AD Genetics Initiative set of families. Among the
SNPs investigated, MnSOD Ala16Val SNP appeared to play a key role.
The relevance of H2O2 imbalance in AD was additionally corroborated
by studies involving GPx SNP. A population study performed by Hong
et al. [126] described an association between GPx activity-decreasing
SNP and AD. Similar results were also found by Maes et al. [127].
Parkinson’s disease (PD) is another important neurodegenerative disor-
der associated with aging. Pathogenesis is directly related to the selective loss
of dopaminergic neurons in the substantia nigra pars compacta and the
degeneration of projecting nerve fibers in the striatum. Although 10% of
PD cases can be explained by specific genetic mutations, the mechanism
responsible for 90% of PD is unknown. In both scenarios, clinical symptoms
Figure 4 The possible relationship of increased superoxide (O2•�) production to the
β-amyloid accumulation. The increased O2•� concentration leads to hydrogen peroxide
(H2O2) content in the cytosol. The increased concentration of H2O2 boosts the produc-tion of the harmful hydroxyl radical (OH•) due to iron (Fe2+)-mediated reaction (Fenton).The harmful OH• induces lipid, protein, and DNA oxidation, leading to neuronal produc-tion of β-amyloid protein.
102 Guilherme Bresciani et al.
Author's personal copy
involve tremor and a profound loss of motor control. PD progression is also
accompanied by perturbations in specific biochemical pathways, including
loss of mitochondrial function [128].
In PD, oxidative stress contributes to dopaminergic neuron degeneration
due to mitochondrial dysfunction and microglial activation which produces
NO• and O2•� during neuro-inflammatory response [128]. Experimental
models, i.e., DJ-1 knockouts in mice, demonstrated that loss of this protein
increased H2O2 in brain [129]. Complementary studies also reported that
DJ-1 inactivation increased MnSOD, thus explaining the concomitant
increase in H2O2[130]. In fact, MnSOD is specifically located in brain
striatum and substantia nigra. It has also been shown that MnSOD, via
the transcription factor FoXO, can prevent the loss of dopaminergic neu-
rons in a Drosophila melanogaster Parkinson’s model (PINK-null) [131]. An
investigation performed by Wang et al. [132] found that the AA genotype
of the MnSOD Ala16Val SNP was significantly associated with PD in 405
Taiwanese patients. As previously mentioned, the Ala variant has been
shown to improve MnSOD-processing efficiency, resulting in increased
MnSOD mRNA and protein tetramers in the mitochondria. However,
studies performed by Singh et al. [133] and Grasbon-Frodl et al. [134]
were contradictory, suggesting gene–environment or gene–gene interac-
tions between PD and MnSOD. This hypothesis is corroborated by a
study by Fong et al. [135], which found an association between the
Ala allele and PD in subjects exposed to pesticide. Similar to AD,
increased MnSOD enzyme efficiency could increase vulnerability to
development of PD.
Ischemic stroke results from obstruction within vessels supplying blood
to the brain. This phenomenon is generally associated with atherosclerosis
caused by fatty deposits lining on the vessel walls. In ischemic stroke, i.e.,
“cerebrovascular accident,” interruption of blood circulation in the ische-
mic vessel causes a bioenergetic collapse [136]. Clinical management of
ischemia involves the administration of pharmacological agents to dissolve
the clot and restore blood flow [137]. Unfortunately, this process causes a
secondary wave of ROS generation from enzymes such as xanthine oxidase
during reperfusion leading to increased O2•�. Because MnSOD efficiency is
crucial to avoid cerebral damage, it is important to clarify its role in O2•�-
mediated pathways. InMnSOD knockouts, lack of this antioxidant enzyme
exacerbated ischemic brain damage via increased oxidative stress and DNA
oxidation [138]. Another study performed by Huang et al. [139] evaluated
the protective effect of a MnSOD-mimetic compound,MnTm4PyP. In this
103Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
study, mice with middle cerebral artery occlusion were used. Animals
pretreated with MnTm4PyP decreased oxidative stress and apoptosis in
ischemic brain cells and tissues. As such, MnSOD could be an effective ther-
apeutic target in ischemic stroke prevention.
Psychiatric diseases affect a large number of individuals worldwide.
Among these, schizophrenia is a devastating disorder present in �1% of
the population. Because neural cells are highly susceptible to oxidative dam-
age [140], a number of studies have suggested a role for oxidative stress in the
development of schizophrenia. Oxidative stress involving ROS-mediated
damage in the CNS can result from inefficient antioxidant defense and/or
increased ROS [141]. Studies have indicated that the abnormal activity of
critical antioxidant enzymes, such as MnSOD, might be a risk factor for
schizophrenia and/or tardive dyskinesia (TD). In fact, previous studies have
suggested that schizophrenic subjects have increased O2•� versus healthy
individuals [142,143]. Flatow et al. [144] performed a meta-analysis of oxi-
dative stress in schizophrenia that evaluated clinical status and antipsychotic
treatment after an acute exacerbation of psychosis. Based on the 44 studies,
the authors found that total antioxidant status was associated with psychotic
state, i.e., plasma level was significantly decreased in patients who presented
with first episode psychosis (FEP). In contrast, total antioxidant status was
significantly increased in patients undergoing antipsychotic treatment for
acute exacerbations of psychosis. SOD was decreased in FEP and acutely
relapsed patients. Decreased antioxidant enzymes, i.e., SOD, was also
described by Tsai et al. [145] in schizophrenia.
A number of studies evaluated the relationship between MnSOD
Ala16Val SNP and schizophrenia. Unfortunately, most data indicated that
this SNP did not directly affect susceptibility although the Val allele was cor-
related with negative schizophrenic symptoms and TD in some populations.
A recent study by Zhang et al. [146] also described the association between
the MnSOD Ala allele and cognitive impairment in schizophrenia. Due to
its dual role in the CNS, lack of association between schizophrenia and this
SNP may result from gene–gene interaction, disease stage or associated
symptoms. It should be pointed out that pharmacologic treatment could also
influence these results. MnSOD imbalance itself may contribute to this dis-
order and/or its symptoms. The enzyme may, however, play a role in other
prevalent psychiatric diseases, i.e., depression and mood disorders. Given
their protective effect against brain injury and neuronal death, deficiency
of antioxidant enzymes may contribute to other mood disorders such as
104 Guilherme Bresciani et al.
Author's personal copy
major depressive disorder (MDD) and bipolar I disorder (BD) [147].
Evidence has shown that mood stabilizers or antidepressants can affect the
activity of various antioxidant enzymes, resulting in altered expression in
brain or peripheral blood concentration [148,149].
Recurrent depressive disorder (rDD) is among the most commonly
diagnosed disabling diseases. This condition appears to involve immune-
inflammatory andoxidative/nitrosative stress.However, studies investigating
the association between MnSOD levels and rDD have been contradictory.
Although increased SOD in rDD was found in some studies [150], others
found decreased SOD during the bipolar disorder depressive phase [151].
Genetic studies demonstrated a potential association between the MnSOD
Ala16Val SNPanddepressionormooddisorders.Gałecki et al. [152] reported
that the Val allele was associated with the development and course of depres-
sion. Curmucu et al. [153] also investigated the etiopathogenetic role of
MnSOD and enzyme-associated SNP in MDD and BD. Although these
authors did not find an associationwith theMnSODAla16Val SNP, the study
was limited by low number of participants (n<100).
4.2. Metabolic-related conditionsThe liver plays a key role in systemic metabolic modulation via glycogen
storage, gluconeogenesis, and the Cori cycle. Given its major metabolic role,
it has been suggested that ROS-mediated damage may play a major role in
liver disease, i.e., steatosis, hereditary hemochromatosis (HHC), hepatocel-
lular carcinoma (HCC), and alcohol-related conditions [154–156].
Increased ROS-mediated damage resulting in lipid peroxidation has
been observed in nonalcoholic fatty liver disease, alcoholic liver disease,
and steatosis [156,157]. Oxidative stress has been reported as the most rel-
evant and fibrogenesis-associated pathology in HHC [155]. Fibrosis in hep-
atitis C virus (HCV)-infected liver is associated with increased
malondialdehyde (MDA), 8-OhdG, and 8-isoprostrane [158–160]. Simi-
larly, electron paramagnetic resonance indicated that ROS increased two
to fivefold in the liver chronic hepatitis C (CHC) patients [161]. Biochem-
ical assays demonstrated increased oxidative stress markers in lymphocytes of
chronic and HCV patients [162]. ROS-related damage implicated in liver
disease is associated with diminished oxidative capacity of HCV patients
[163]. Oxidative stress is known to be one of the main HCV-related hepa-
tocyte proliferative mechanisms leading to HCC.
105Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
Mitochondria are mediators of receptor-induced cell death in hepato-
cytes [164,165]. The mitochondrial-related death pathway may be triggered
by different stimuli including increased ROS production [165]. Apoptotic
pathways include release of proteins, i.e., cytochrome c (Cyt c), Smac/
DIABLO, apoptosis-inducing factor (AIF), and endonuclease G, normally
located in the mitochondrial intermembrane space [166,167]. Release of
these proteins results in cytosolic protease activation or nuclear transloca-
tion, causing apoptosis, DNA fragmentation, and chromatin condensation
(Fig. 5) [164].
Increased circulating O2•� has been found in decompensated cirrhosis
[169]. Hepatic steatosis has also been implicated in mitochondrial
Figure 5 Release of mitochondrial apoptotic factors. The cytochrome c (Cyt c) reachesthe cytosol and interacts with the apoptosis protease-activating factor-1 (Apaf-1) whichproduces an apoptosome for caspase-9 activation; the caspase-9 activation ultimatelyinduces caspase-3-mediated cell death. The X-linked inhibitor of apoptosis protein(XIAP) is able to block caspases-3 and -9 action, although the second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with a lowisoelectric point (Smac/DIABLO) and high temperature requirement protein A2 andstress-regulated endoprotease (HtrA2/Omi) neutralizes XIAP. The apoptosis-inducingfactor (AIF) is another apoptogenic molecule which is also released from the mitochon-dria. The AIF translocates into the nucleus and triggers DNA fragmentation and chro-matin condensation. Adapted from Ref. [168].
106 Guilherme Bresciani et al.
Author's personal copy
dysfunction with concomitant ROS formation leading to lipid peroxida-
tion, cytokine induction, and steatohepatitis [154]. MnSOD activity is
higher in liver versus other human tissues, i.e., brain and skeletal muscle
[170]. In viral hepatitis, increased MnSOD represents an adaptive response
to the oxidative stress-related pathways (infection persistence and damage
progression) [171]. Additionally, viruses may alter mitochondrial function,
inducing oxidative stress through organelle association and lead to the acti-
vation of different apoptosis and proliferation transcription factors, such as
p38, MAPK, and JNK (via AP-1), that upregulates hepatic MnSOD
[171,172]. Given its mitochondrial location, MnSOD may be a marker of
hepatic oxidative stress-induced disorders [173].
Increased MnSOD has been proposed as a marker for early HCC [173]
and chronic hepatitis [174]. Child-Pugh class A liver cirrhosis patients also
have increased serumMnSOD [172]. MnSODmay be induced by different
stimuli, such as ROS, cytokines, and ethanol [175] and this upregulation
decreased cellular O2•�[176] and ONOO� produced by NO•–O2
•� reac-
tion that may play an important role in alcohol-induced liver injury [177].
As such, MnSOD upregulation may not be exclusively related to ROS-
mediated cell adaptation. It may be relevant, however, in cell proliferation
and tumor growth regulation via O2•� dismutation [172].
Excessive oxidative stress has been implicated as a major factor in the
onset of diabetes [23], which may lead to myocardial ischemia and reperfu-
sion injury [178]. It has been suggested that the upstream event for devel-
opment of diabetes involves mitochondrial ROS overproduction [12]. In
fact, O2•� production is considered a causal link between increased glucose
and development of vascular complications [179,180]. Normalization of
high glucose-cultured endothelial cells by MnSOD overexpression
suggested that mitochondrial respiration acts as a major source of oxidative
stress in diabetes [105,181].
Currently, it is known that several obesity-related conditions, i.e., ath-
erosclerosis, are associated with increased ROS production. Oxidative stress
and redox status have been studied in young populations to determine the
possible metabolic modulation of theO2 pathway. Isoprostane was increased
in obese children with increased blood pressure [182]. Levels were positively
correlated with metabolic risk factors in severe childhood obesity [24].
MDAwas inversely correlated with high-density lipoprotein (HDL) choles-
terol in these children and HDL was negatively correlated with advanced
oxidation protein products. Similarly, childhood obesity affected redox sta-
tus markers, such as reduced plasma α-tocopherol and ascorbic acid
107Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
[183,184]. Zhu et al. [184] found decreased SOD and CAT activities in
obese children. Only one study investigated the influence of Ala16Val on
childhood obesity [185]. Although obesity was not associated with this
SNP, environmental factors were not considered.
The Ala16Val SNP has been associated with different metabolic-related
conditions. The Val allele and Val/Val genotype have been associated with
nephropathy in diabetic patients [186,187]. In contrast, the Val/Val geno-
type was associated with increased risk for diabetic nephropathy when con-
trolled for gender [188]. Val allele carriers and the homozygous Val
genotype were associated with a higher risk of neuropathy in diabetics
[189] and the Val/Val genotype was associated with diabetic retinopathy
[190]. The Ala allele and homozygous Ala genotype were found in another
diabetic retinopathy population [191]. Interestingly, the homozygous
Val/Val genotype has also been correlated with poorer control in diabetics
with or without macroangiopathy [192]. Recently, a combination of the
Ala16Val with GPx1 and CAT SNPs has been associated with increased
plasma triglyceride in type 2 diabetes mellitus and diabetic CAD [193].
Previous clinical studies from our research group have described the asso-
ciation between the Val allele and metabolic diseases associated with athero-
sclerotic risk, i.e., hypercholesterolemia [194] and obesity [195]. The Val
allele was also associated with increased oxidized low-density lipoprotein
(ox-LDL) especially in type 2 diabetics [196]. Increased inflammatory cyto-
kines have also been noted [197]. It is uncertain if these findings can be
applied to children. Future genetic studies should consider the possible role
of the MnSOD Ala16Val SNP in childhood obesity.
4.3. Cardiovascular systemMitochondrial ROS production has been implicated in several
cardiovascular-related disorders, i.e., atherosclerosis, hypertension, and dia-
betes [21]. Oxidative stress due to increased O2•� has been demonstrated in
peripheral blood vessels during hypertension [22]. Consequently, hyperten-
sion increases vascular production of O2•� leading to inactivation of
NO•-mediated endothelium-dependent vasodilatation (Fig. 6) [199]. The
myocardium is equipped with endogenous enzymatic and nonenzymatic
antioxidant systems capable of metabolizing ROS generated during normal
cellular activity [200]. Evidence of increased myocardial oxidative stress and
108 Guilherme Bresciani et al.
Author's personal copy
ROS production has been observed in animal models of heart failure and has
been implicated in the pathogenesis of cardiac injury and the progression of
heart failure [11]. Decreased MnSOD during acute to chronic phase disease
development in infected murine myocardium has been reported [201].
Atherosclerosis is a complex disease process associated with risk factors
including hypertension, hyperlipidemia, and genetic makeup [202,203].
Atherosclerosis can be considered a chronic inflammatory process with
underlying abnormal redox state in the vascular cell wall [204,205]. As such,
lipoprotein oxidation, especially LDL, is considered to be a key event in its
pathogenesis [206–208]. Furthermore, cholesterol oxidation products
(ChOx) have been reported as the major cytotoxic components of
ox-LDL and stimulate cholesterol accumulation in vascular cells [208]. For-
tunately, MnSOD overexpression inhibits atherosclerosis [209].
Several studies have used different MnSOD knockouts to elucidate its
role in cardiovascular-related diseases. Notably, MnSOD knockouts die
prematurely from dilated cardiomyopathy within several weeks of birth
Figure 6 Cardiovascular disease-related factors andmitochondrial ROS production. Theincreased superoxide (O2
•�) production leads to a cascade of ROS production and redoxstate disruption. While the combination of O2
•� with nitric oxide (NO•) impairs vasodi-latation, its reaction with peroxynitrite (ONOO�) leads to MnSOD inactivation and oxi-dation of low-density lipoprotein (ox-LDL). At this stage, a mitochondrial dysfunctiondue to increased membrane permeability (Δψ ) may take place, with hydroxyl radical(OH•) formation due to iron (Fe2+) release. These alterations increase cardiovascular(CVD)-related risk factors. Adapted from Ref. [198].
109Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
and show increased hepatic lipid content and neurodegeneration
[85,210,211]. Knockouts had substantial reduction in mitochondrial
enzyme activity, i.e., complexes I–III and aconitase [212]. As a result, geno-
mic DNA from knockouts had significant oxidative damage [213]. Similarly,
an ApoE�/� model demonstrated that MnSOD was responsible for an
endothelial function-associated O2•� increase which caused mitochondrial
damage. The same knockout model demonstrated mitochondrial dysfunc-
tion, increased mtDNA damage, and accelerated atherosclerosis. Thus,
MnSOD has been strongly implicated in endothelial function via NO•
and ROS within mitochondria.
In murine brain, intracerebroventricular MnSOD injection reduced
angiotensin II-induced increases in heart rate, blood pressure, and drinking
behavior [214]. Additionally, the overexpression of MnSOD or a
mitochondrially targetedmitoTEMPOSODmimetic improved endothelial
function, reduced hypertension and oxidative stress in angiotensin II or
DOCA salt-induced hypertensive mice [215]. Moreover, it has been shown
that pulmonary arterial hypertension is increased by the epigenetic attenu-
ation of MnSOD [216]. An angiogenesis study revealed that MnSOD over-
expression induced H2O2 production which stimulated endothelial cell
sprouting and neovascularization [217]. Furthermore, it has been reported
that vascular endothelial growth factor (VEGF) induced MnSOD
upregulation in human cell culture, which may represent a ROS-induced
H2O2 mechanism to enhance angiogenesis [218]. These findings indicate
the relevant role for MnSOD in mitochondrial O2•� detoxification. The
mechanisms implicated in heart failure progression suggest that ROS plays
a major role [219,220]. Pericardial fluid and peripheral blood ROS markers
have been detected in heart failure [221–223] and hypertension [22].
The Ala16Val SNP has been associated with high intima media thickness
and plasma LDL concentration in hypertensive Val carrier females [207]. Ala
carriers were more prone to arsenic-related hypertension [224]. Cardiomy-
opathy was more prevalent in Val carriers with unrelated hemochromatosis.
Ala/Val and Val/Val exhibited increased ox-LDL suggesting that Val carrier
status was an independent factor for ox-LDL [196]. The Ala variant
decreased risk for coronary artery disease and acute myocardial infarction
by upregulated MnSOD and reduced ox-LDL apoptosis [225]. The Val
allele has also been associated with vasospastic angina pectoris with the
Val/Val genotype as an independent risk factor [226]. Cardiogenic shock
has been correlated with the Val allele in dilated cardiopathy [227].
110 Guilherme Bresciani et al.
Author's personal copy
5. ENVIRONMENTAL FACTORS, GENETICS, AND MnSODMODULATION
Despite epidemiologic evidence, the role of Ala16Val SNP on
MnSODmodulation remains unclear [101]. Studies have evaluated this rela-
tionship in conjunction with environmental factors known to influence
ROS, i.e., smoking and alcohol intake, for example [228–232]. Ambrosone
et al. [32] demonstrated that epigenetic factors may be responsible. In this
study, Ala homozygous females with low antioxidant intake had increased
risk of breast cancer. Studies concerning the role of diet are, however, con-
flicting. Although the Ala allele and Ala homozygous genotype were corre-
lated to low antioxidant intake in breast cancer [32,233], the Val/Val
genotype increased the prevalence of aggressive prostate cancer in males
with increased iron intake [234]. To provide better experimental control,
in vitro assays may serve as a viable option. For example, one study found
that 6 weeks of antioxidant supplementation decreased the Ala allele-
associated DNA damage in isolated human lymphocytes [235]. These
preliminary findings clearly indicate the need for more comprehensive
and better controlled in vitro and in vivo studies.
5.1. Exercise, oxidative stress, and health: Evidence for MnSODinvolvement
The health benefits of regular exercise are well documented [236,237] and
include both psychologic and physiologic benefits to a variety of disorders
such as heart disease, hypertension, and diabetes [238–242]. In fact, regular
exercise has long been associated with improved lipid profile (see Ref. [243]
for a review) and endothelial function in type 1 diabetes [244]. In a
recent report, type 2 diabetics showed lipid profile benefits from aerobic,
resistance, or combined training [245]. Davis et al. [242] found that low-
and/or high-intensity aerobics induced positive effects on insulin resistance
and adiposity in obese children thus decreasing type 2 diabetes-
associated risks.
Exercise reduces primary and secondary cardiovascular events [246] by
enhancing cardiorespiratory fitness. After 8–12 weeks of aerobic training,
subjects with resistant hypertension had decreased blood pressure and
increased performance [247]. Exercise has also been demonstrated to
decrease blood pressure in subjects with low responsiveness to medical
111Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
treatment [247]. The authors concluded that exercise should be included as a
part of the therapeutic approach in those individuals with resistant hyperten-
sion. Patients with CAD demonstrated improvedmaximal exercise capacity,
ventilation threshold, and muscular performance following endurance and
combined endurance/resistance training [248]. Interestingly, the latter
group was also characterized by increased HDL.
In a recent review of CAD and metabolic syndrome, Otani [249]
suggested that aerobic exercise may be the most effective nonpharmacologic
tool for metabolic syndrome management and this improvement occurs
largely through oxidative stress modulation. It is well known that physical
exercise increases the antioxidant capacity of the exercised muscle, which
in turn induces positive adaptive stimuli of redox status [1,31,35,250,251].
The effect of physical exercise on redox balance and MnSOD has been the
subject of many investigations. Studies have reported increased MnSOD
after exercise in general [252–256] and under different experimental
conditions [253,254,257–261]. Recently, MnSOD mRNA expression was
shown to be upregulated by exercise [261–263]. Thus, there is considerable
evidence that exercise training may result in positive MnSOD modulation
through redox-sensitive pathways (Fig. 7).
5.1.1 Exercise and genetics: Where nature and nurture meetThe advent of molecular biology introduced a new field in sport sciences:
molecular exercise physiology as presented by Harridge and Spurway [264].
Over the last decades, exercise physiologists have studied the potential
influence of genetics on exercise outcomes and the relationship among
Figure 7 Effects of regular moderate intensity exercise on mitochondrial quality. Theregular exercise increases the antioxidant defenses and thus reducing oxidative stress.This positivemodulation is reflected on an enhanced redox status, leading to a decreaseon the risk of cardiovascular diseases, neurological and metabolic related. On the oppo-site, sedentarism disrupts the redox state across decreased antioxidant defenses, and ithas been long related to prevalence of noncommunicable diseases, such ascardiovascular- and metabolic-related conditions.
112 Guilherme Bresciani et al.
Author's personal copy
SNP and exercise performance. The role of angiotensin-converting enzyme
in exercise performance related to the cardiovascular system has been exten-
sively investigated [265,266]. Type V (CLOA5A1) and VI collagen
(COL6A1) SNPs were evaluated with respect to their relationship to endur-
ance [267–269]. The α-actinin 3 gene (ACTN3) SNP and its association with
strength exercises have also been studied [270,271]. For additional informa-
tion, the reader is referred to an excellent review on exercise-related benefits
and genetic background [272]. Despite their apparently key role, studies to
assess the influence of SNP on exercise-induced antioxidant enzyme mod-
ulation remain relatively scarce.
Antioxidant enzyme SNPs may imbalance oxidative stress and antioxi-
dant defense following exercise. The role of Ala16Val SNP in exercise has
been recently studied. DNA damage was increased in homozygous Ala
genotype runners [273], whereas the Val allele was associated with increased
muscle damage in females [274]. In our experience, exercise-induced
MnSOD mRNA and enzyme activity in homozygous Ala genotypes and
Val/Val carriers showed decreased thiol content [275]. Additionally, the
Ala/Ala genotype showed increased MnSOD and dose-dependent activity
in the Ala allele carriers, which was reflected by unchanged thiol content
[275]. Heterozygous Ala16Val carriers resulted in decreased DNA damage
and lipid peroxidation with carotenoid-enriched oil supplementation
following exercise [276]. Leukocytes of healthy/trained subjects had
different responses depending on Ala/Val SNP [277]. Overall, these
results indicate that environmental factors may differentially modulate the
response of SNPs to oxidative stress. Unfortunately, studies on the effect
of exercise training on MnSOD Ala16Val SNP modulation have not been
performed to date. As such, whether moderate exercise training would help
prevent disease-associated risks in different Ala16Val carriers remains an
open question.
6. CONCLUSIONS
Oxidative stress has been long associated with disease etiology.
Increased ROS production is known to mediate a few signaling pathways,
the end products of which may alter homeostasis through metabolic disrup-
tion. Lipid peroxidation, protein carbonylation, and DNA damage have all
been found in different disease-related settings, i.e., neuronal- and
metabolic-related conditions. Increased ROS production has been reported
in atherosclerosis and PD. Fortunately, humans have a highly specialized
113Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
antioxidant system that includes both direct ROS quenchers and enzymes.
The enzymatic antioxidant system depends on the powerful MnSOD, a
mitochondrial enzyme, which is the first line of ROS defense in aerobes.
The Ala16Val SNP of this enzyme has been shown to differentially modulate
the enzyme activity within several disease-related conditions, such as neural
and cardiovascular pathologies. Exercise, which is also a potent MnSOD
modulator, has been observed to influence the health of these chronic
and neurologic diseases. Exercise has also been shown to modulateMnSOD
Ala16Val response to stress in different study populations. However, the role
of exercise training to promote antioxidant adaptation viaMnSODAla16Val
modulation remains unanswered. Elucidation of the interplay between
environmental and genetic factors in disease-related conditions may help
to identify alternative strategies to maintain, prevent, and in some cases treat
chronic disease.
ACKNOWLEDGMENTSThe authors are indebted to Leonardo Barili Brandi for technical support with figure editing.
The Laboratorio de Biogenomica is funded by CNPq, FAPERGS, CAPES, and FAPEAM.
CIBERehd is funded by the Instituto de Salud Carlos III, Spain.
REFERENCES[1] P. Johnson, Antioxidant enzyme expression in health and disease: effects of exercise
and hypertension, Comp. Biochem. Physiol. C: Toxicol. Pharmacol. 133 (2002)493–505.
[2] Q. Cai, X.O. Shu,W.Wen, J.R. Cheng, Q. Dai, Y.T. Gao,W. Zheng, Genetic poly-morphism in the manganese superoxide dismutase gene, antioxidant intake, and breastcancer risk: results from the Shanghai Breast Cancer Study, Breast Cancer Res.6 (2004) R647–R655.
[3] C.K. Sen, Antioxidant and redox regulation of cellular signaling: introduction, Med.Sci. Sports Exerc. 33 (2001) 368–370.
[4] A. Boveris, B. Chance, The mitochondrial generation of hydrogen peroxide. Generalproperties and effect of hyperbaric oxygen, Biochem. J. 134 (1973) 707–716.
[5] C. Triantaphylides, M. Havaux, Singlet oxygen in plants: production, detoxificationand signaling, Trends Plant Sci. 14 (2009) 219–228.
[6] L.L. Ji, M.C. Gomez-Cabrera, J. Vina, Role of nuclear factor kappaB and mitogen-activated protein kinase signaling in exercise-induced antioxidant enzyme adaptation,Appl. Physiol. Nutr. Metab. 32 (2007) 930–935.
[7] M.J. Czaja, Cell signaling in oxidative stress-induced liver injury, Semin. Liver Dis.27 (2007) 378–389.
[8] B. Saberi, M. Shinohara, M.D. Ybanez, N. Hanawa, W.A. Gaarde, N. Kaplowitz,D. Han, Regulation of H(2)O(2)-induced necrosis by PKC and AMP-activated kinasesignaling in primary cultured hepatocytes, Am. J. Physiol. Cell Physiol. 295 (2008)C50–C63.
114 Guilherme Bresciani et al.
Author's personal copy
[9] H.M. Alessio, A.E. Hagerman, B.K. Fulkerson, J. Ambrose, R.E. Rice, R.L. Wiley,Generation of reactive oxygen species after exhaustive aerobic and isometric exercise,Med. Sci. Sports Exerc. 32 (2000) 1576–1581.
[10] D. Harman, Aging: a theory based on free radical and radiation chemistry, J. Gerontol.11 (1956) 298–300.
[11] F. Sam, D.L. Kerstetter, D.R. Pimental, S. Mulukutla, A. Tabaee, M.R. Bristow,W.S. Colucci, D.B. Sawyer, Increased reactive oxygen species production and func-tional alterations in antioxidant enzymes in human failing myocardium, J. Card. Fail.11 (2005) 473–480.
[12] F. Giacco, M. Brownlee, Oxidative stress and diabetic complications, Circ. Res.107 (2010) 1058–1070.
[13] B. Kadenbach, R. Ramzan, S. Vogt, Degenerative diseases, oxidative stress and cyto-chrome c oxidase function, Trends Mol. Med. 15 (2009) 139–147.
[14] S.K. Powers, J. Duarte, A.N. Kavazis, E.E. Talbert, Reactive oxygen species are sig-nalling molecules for skeletal muscle adaptation, Exp. Physiol. 95 (2010) 1–9.
[15] J. Pourova, M. Kottova, M. Voprsalova, M. Pour, Reactive oxygen and nitrogen spe-cies in normal physiological processes, Acta Physiol (Oxf.) 198 (2010) 15–35.
[16] P.D. Ray, B.W. Huang, Y. Tsuji, Reactive oxygen species (ROS) homeostasis andredox regulation in cellular signaling, Cell. Signal. 24 (2012) 981–990.
[17] B. Commoner, J. Townsend, G.E. Pake, Free radicals in biological materials, Nature174 (1954) 689–691.
[18] I. Margaritis, A.S. Rousseau, Does physical exercise modify antioxidant requirements?Nutr. Res. Rev. 21 (2008) 3–12.
[19] S. Judge, C. Leeuwenburgh, Cardiac mitochondrial bioenergetics, oxidative stress, andaging, Am. J. Physiol. Cell Physiol. 292 (2007) C1983–C1992.
[20] G. Lopez-Lluch, P.M. Irusta, P. Navas, R. de Cabo, Mitochondrial biogenesis andhealthy aging, Exp. Gerontol. 43 (2008) 813–819.
[21] D.X. Zhang, D.D. Gutterman, Mitochondrial reactive oxygen species-mediated sig-naling in endothelial cells, Am. J. Physiol. Heart Circ. Physiol. 292 (2007)H2023–H2031.
[22] G. Zalba, G. San Jose, M.U. Moreno, M.A. Fortuno, A. Fortuno, F.J. Beaumont,J. Diez, Oxidative stress in arterial hypertension: role of NAD(P)H oxidase,Hypertension 38 (2001) 1395–1399.
[23] J.L. Rains, S.K. Jain, Oxidative stress, insulin signaling, and diabetes, Free Radic. Biol.Med. 50 (2011) 567–575.
[24] P. Codoner-Franch, S. Tavarez-Alonso, R. Murria-Estal, M. Tortajada-Girbes,R. Simo-Jorda, E. Alonso-Iglesias, Elevated advanced oxidation protein products(AOPPs) indicate metabolic risk in severely obese children, Nutr. Metab. Cardiovasc.Dis. 22 (2012) 237–243.
[25] A. Nunomura, K. Honda, A. Takeda, K. Hirai, X. Zhu, M.A. Smith, G. Perry, Oxi-dative damage to RNA in neurodegenerative diseases, J. Biomed. Biotechnol.2006 (2006) 82323.
[26] G.C. Higgins, P.M. Beart, Y.S. Shin, M.J. Chen, N.S. Cheung, P. Nagley, Oxidativestress: emerging mitochondrial and cellular themes and variations in neuronal injury,J. Alzheimers Dis. 20 (Suppl. 2) (2010) S453–S473.
[27] S.C. Correia, R.X. Santos, G. Perry, X. Zhu, P.I. Moreira, M.A. Smith, Mitochon-dria: the missing link between preconditioning and neuroprotection, J. AlzheimersDis. 20 (Suppl. 2) (2010) S475–S485.
[28] M.F. Beal, Mitochondria take center stage in aging and neurodegeneration, Ann.Neurol. 58 (2005) 495–505.
[29] M.P. Mattson, M. Gleichmann, A. Cheng, Mitochondria in neuroplasticity and neu-rological disorders, Neuron 60 (2008) 748–766.
115Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
[30] D. Pessayre, Role of mitochondria in non-alcoholic fatty liver disease, J. Gastroenterol.Hepatol. 22 (Suppl. 1) (2007) S20–S27.
[31] S. Sachdev, K.J. Davies, Production, detection, and adaptive responses to free radicalsin exercise, Free Radic. Biol. Med. 44 (2008) 215–223.
[32] C.B. Ambrosone, J.L. Freudenheim, P.A. Thompson, E. Bowman, J.E. Vena,J.R. Marshall, S. Graham, R. Laughlin, T. Nemoto, P.G. Shields, Manganese super-oxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk ofbreast cancer, Cancer Res. 59 (1999) 602–606.
[33] D.C. Wallace, S. Melov, Radicals r’aging, Nat. Genet. 19 (1998) 105–106.[34] M. Edeas, Strategies to target mitochondria and oxidative stress by antioxidants: key
points and perspectives, Pharm. Res. 28 (2011) 2771–2779.[35] J. Finaud, G. Lac, E. Filaire, Oxidative stress : relationship with exercise and training,
Sports Med. 36 (2006) 327–358.[36] B. Vurusaner, G. Poli, H. Basaga, Tumor suppressor genes and ROS: complex net-
works of interactions, Free Radic. Biol. Med. 52 (2012) 7–18.[37] C. Leeuwenburgh, J.W. Heinecke, Oxidative stress and antioxidants in exercise, Curr.
Med. Chem. 8 (2001) 829–838.[38] R.R. Tao, Y.L. Ji, Y.M. Lu, K. Fukunaga, F. Han, Targeting nitrosative stress for neu-
rovascular protection: new implications in brain diseases, Curr. Drug Targets 13 (2012)272–284.
[39] I. Afanas’ev, ROS and RNS signaling in heart disorders: could antioxidant treatmentbe successful? Oxid. Med. Cell. Longev. 2011 (2011) 293769.
[40] K. Stadler, Peroxynitrite-driven mechanisms in diabetes and insulin resistance—thelatest advances, Curr. Med. Chem. 18 (2011) 280–290.
[41] W. Zhong, L.W. Oberley, T.D. Oberley, D.K. St Clair, Suppression of the malignantphenotype of human glioma cells by overexpression of manganese superoxide dis-mutase, Oncogene 14 (1997) 481–490.
[42] J.M. Mates, J.M. Segura, C. Perez-Gomez, R. Rosado, L. Olalla, M. Blanca,F.M. Sanchez-Jimenez, Antioxidant enzymatic activities in human blood cells afteran allergic reaction to pollen or house dust mite, Blood Cells Mol. Dis. 25 (1999)103–109.
[43] K. Kannan, S.K. Jain, Oxidative stress and apoptosis, Pathophysiology 7 (2000)153–163.
[44] U. Landmesser, D.G. Harrison, Oxidant stress as a marker for cardiovascular events:Ox marks the spot, Circulation 104 (2001) 2638–2640.
[45] J. Milei, P. Forcada, C.G. Fraga, D.R. Grana, G. Iannelli, M. Chiariello, I. Tritto,G. Ambrosio, Relationship between oxidative stress, lipid peroxidation, and ultra-structural damage in patients with coronary artery disease undergoing cardioplegicarrest/reperfusion, Cardiovasc. Res. 73 (2007) 710–719.
[46] J.J. Garcia, R.J. Reiter, J.M. Guerrero, G. Escames, B.P. Yu, C.S. Oh, A. Munoz-Hoyos, Melatonin prevents changes in microsomal membrane fluidity during inducedlipid peroxidation, FEBS Lett. 408 (1997) 297–300.
[47] B. Hennig, C.K. Chow, Lipid peroxidation and endothelial cell injury: implications inatherosclerosis, Free Radic. Biol. Med. 4 (1988) 99–106.
[48] G. Barrera, Oxidative stress and lipid peroxidation products in cancer progression andtherapy, ISRN Oncol. 2012 (2012) 137289.
[49] N. Ercal, H. Gurer-Orhan, N. Aykin-Burns, Toxic metals and oxidative stress part I:mechanisms involved in metal-induced oxidative damage, Curr. Top. Med. Chem.1 (2001) 529–539.
[50] V.N. Pivtoraiko, S.L. Stone, K.A. Roth, J.J. Shacka, Oxidative stress and autophagy inthe regulation of lysosome-dependent neuron death, Antioxid. Redox Signal.11 (2009) 481–496.
116 Guilherme Bresciani et al.
Author's personal copy
[51] N. Garcia, F. Correa, E. Chavez, On the role of the respiratory complex I onmembrane permeability transition, J. Bioenerg. Biomembr. 37 (2005) 17–23.
[52] K. Venkataraman, S. Khurana, T.C. Tai, Oxidative stress in aging—matters of theheart and mind, Int. J. Mol. Sci. 14 (2013) 17897–17925.
[53] R.C. Bollineni, R. Hoffmann, M. Fedorova, Proteome-wide profiling ofcarbonylated proteins and carbonylation sites in HeLa cells under mild oxidative stressconditions, Free Radic. Biol. Med. 68 (2014) 186–195.
[54] C. Nathan, A. Ding, SnapShot: reactive oxygen intermediates (ROI), Cell 140 (2010),951–951.e952.
[55] T.C. Squier, Oxidative stress and protein aggregation during biological aging, Exp.Gerontol. 36 (2001) 1539–1550.
[56] K. Hitschke, R. Buhler, H.J. Apell, G. Stark, Inactivation of the Na, K-ATPase byradiation-induced free radicals. Evidence for a radical-chain mechanism, FEBS Lett.353 (1994) 297–300.
[57] F.L. Muller, A.G. Roberts, M.K. Bowman, D.M. Kramer, Architecture of the Qo siteof the cytochrome bc1 complex probed by superoxide production, Biochemistry42 (2003) 6493–6499.
[58] G. Lenaz, R. Fato, M.L. Genova, C. Bergamini, C. Bianchi, A. Biondi, Mitochondrialcomplex I: structural and functional aspects, Biochim. Biophys. Acta 1757 (2006)1406–1420.
[59] A.J. Lambert, M.D. Brand, Inhibitors of the quinone-binding site allow rapid super-oxide production from mitochondrial NADH:ubiquinone oxidoreductase (complexI), J. Biol. Chem. 279 (2004) 39414–39420.
[60] J.R. Smith, N.E. Kay, A.J. Gottlieb, F.A. Oski, Abnormal erythrocyte metabolism inhepatic disease: effect of NADP repletion, Am. J. Hematol. 6 (1979) 313–321.
[61] P.G. Wells, G.P. McCallum, K.C. Lam, J.T. Henderson, S.L. Ondovcik, OxidativeDNA damage and repair in teratogenesis and neurodevelopmental deficits, BirthDefects Res. C Embryo Today 90 (2010) 103–109.
[62] M. Mahmoudi, J. Mercer, M. Bennett, DNA damage and repair in atherosclerosis,Cardiovasc. Res. 71 (2006) 259–268.
[63] C. Chatgilialoglu, P. O’Neill, Free radicals associated with DNA damage, Exp.Gerontol. 36 (2001) 1459–1471.
[64] E. Napoli, S.Wong, C. Giulivi, Evidence of reactive oxygen species-mediated damageto mitochondrial DNA in children with typical autism, Mol. Autism 4 (2013) 2.
[65] Z. Ding, S. Liu, X. Wang, M. Khaidakov, Y. Dai, J.L. Mehta, Oxidant stress in mito-chondrial DNA damage, autophagy and inflammation in atherosclerosis, Sci. Rep.3 (2013) 1077.
[66] D.R. Crawford, N.E. Abramova, K.J. Davies, Oxidative stress causes a general,calcium-dependent degradation of mitochondrial polynucleotides, Free Radic. Biol.Med. 25 (1998) 1106–1111.
[67] J. Gonzalez-Gallego, M.V. Garcia-Mediavilla, S. Sanchez-Campos, M.J. Tunon,Fruit polyphenols, immunity and inflammation, Br. J. Nutr. 104 (Suppl. 3) (2010)S15–S27.
[68] I. Crespo, M.V. Garcia-Mediavilla, M. Almar, P. Gonzalez, M.J. Tunon, S. Sanchez-Campos, J. Gonzalez-Gallego, Differential effects of dietary flavonoids on reactiveoxygen and nitrogen species generation and changes in antioxidant enzyme expressioninduced by proinflammatory cytokines in Chang Liver cells, Food Chem. Toxicol.46 (2008) 1555–1569.
[69] A. Borrelli, A. Schiattarella, P. Bonelli, F.M. Tuccillo, F.M. Buonaguro, A. Mancini,The functional role of MnSOD as a biomarker of human diseases and therapeuticpotential of a new isoform of a human recombinant MnSOD, Biomed. Res. Int.2014 (2014) 476789.
117Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
[70] T. Shimizu, H. Nojiri, S. Kawakami, S. Uchiyama, T. Shirasawa, Model mice fortissue-specific deletion of the manganese superoxide dismutase gene, Geriatr.Gerontol. Int. 10 (Suppl. 1) (2010) S70–S79.
[71] S.K. Powers, M.J. Jackson, Exercise-induced oxidative stress: cellular mechanisms andimpact on muscle force production, Physiol. Rev. 88 (2008) 1243–1276.
[72] M. Fransen, M. Nordgren, B. Wang, O. Apanasets, Role of peroxisomes in ROS/RNS-metabolism: implications for human disease, Biochim. Biophys. Acta1822 (2012) 1363–1373.
[73] J.R. Drevet, The antioxidant glutathione peroxidase family and spermatozoa: a com-plex story, Mol. Cell. Endocrinol. 250 (2006) 70–79.
[74] R. Brigelius-Flohe, Tissue-specific functions of individual glutathione peroxidases,Free Radic. Biol. Med. 27 (1999) 951–965.
[75] H.N. Kirkman, G.F. Gaetani, Mammalian catalase: a venerable enzymewith newmys-teries, Trends Biochem. Sci. 32 (2007) 44–50.
[76] F. Antunes, D. Han, E. Cadenas, Relative contributions of heart mitochondria gluta-thione peroxidase and catalase to H(2)O(2) detoxification in in vivo conditions, FreeRadic. Biol. Med. 33 (2002) 1260–1267.
[77] V.C. Culotta, M. Yang, T.V. O’Halloran, Activation of superoxide dismutases: put-ting the metal to the pedal, Biochim. Biophys. Acta 1763 (2006) 747–758.
[78] Z. Qin, K.J. Reszka, T. Fukai, N.L. Weintraub, Extracellular superoxide dismutase(ecSOD) in vascular biology: an update on exogenous gene transfer and endogenousregulators of ecSOD, Transl. Res. 151 (2008) 68–78.
[79] R. Mancuso, R. Osta, X. Navarro, Pre-symptomatic electrophysiological tests predictclinical onset and survival in SOD1 ALS mice, Muscle Nerve 50 (2014) 943–949.
[80] H. Yang, G. Wang, H. Sun, R. Shu, T. Liu, C.E. Wang, Z. Liu, Y. Zhao, B. Zhao,Z.Ouyang,D.Yang, J.Huang,Y.Zhou, S. Li,X. Jiang,Z.Xiao,X.J. Li, L.Lai, Species-dependent neuropathology in transgenic SOD1 pigs, Cell Res. 24 (2014) 464–481.
[81] D.D. Heistad, Oxidative stress and vascular disease: 2005 Duff lecture, Arterioscler.Thromb. Vasc. Biol. 26 (2006) 689–695.
[82] J. Oshikawa, N. Urao, H.W. Kim, N. Kaplan, M. Razvi, R. McKinney, L.B. Poole,T. Fukai, M. Ushio-Fukai, Extracellular SOD-derived H2O2 promotes VEGF signal-ing in caveolae/lipid rafts and post-ischemic angiogenesis in mice, PLoS One 5 (2010)e10189.
[83] M. Strassburger, W. Bloch, S. Sulyok, J. Schuller, A.F. Keist, A. Schmidt, J. Wenk,T. Peters, M. Wlaschek, J. Lenart, T. Krieg, M. Hafner, A. Kumin, S. Werner,W. Muller, K. Scharffetter-Kochanek, Heterozygous deficiency of manganese super-oxide dismutase results in severe lipid peroxidation and spontaneous apoptosis inmurine myocardium in vivo, Free Radic. Biol. Med. 38 (2005) 1458–1470.
[84] S.K. Dhar, J. Tangpong, L. Chaiswing, T.D. Oberley, D.K. St Clair, Manganesesuperoxide dismutase is a p53-regulated gene that switches cancers between earlyand advanced stages, Cancer Res. 71 (2011) 6684–6695.
[85] R.M. Lebovitz, H. Zhang, H. Vogel, J. Cartwright Jr., L. Dionne, N. Lu, S. Huang,M.M. Matzuk, Neurodegeneration, myocardial injury, and perinatal death in mito-chondrial superoxide dismutase-deficient mice, Proc. Natl. Acad. Sci. U.S.A93 (1996) 9782–9787.
[86] M.D. Williams, H. Van Remmen, C.C. Conrad, T.T. Huang, C.J. Epstein,A. Richardson, Increased oxidative damage is correlated to altered mitochondrialfunction in heterozygous manganese superoxide dismutase knockout mice, J. Biol.Chem. 273 (1998) 28510–28515.
[87] H. Van Remmen, M.D. Williams, Z. Guo, L. Estlack, H. Yang, E.J. Carlson,C.J. Epstein, T.T. Huang, A. Richardson, Knockout mice heterozygous for Sod2
118 Guilherme Bresciani et al.
Author's personal copy
show alterations in cardiac mitochondrial function and apoptosis, Am. J. Physiol. HeartCirc. Physiol. 281 (2001) H1422–H1432.
[88] H. Van Remmen, Y. Ikeno, M. Hamilton, M. Pahlavani, N. Wolf, S.R. Thorpe,N.L. Alderson, J.W. Baynes, C.J. Epstein, T.T. Huang, J. Nelson, R. Strong,A. Richardson, Life-long reduction in MnSOD activity results in increased DNAdamage and higher incidence of cancer but does not accelerate aging, Physiol. Geno-mics 16 (2003) 29–37.
[89] S. Miriyala, I. Spasojevic, A. Tovmasyan, D. Salvemini, Z. Vujaskovic, D. St Clair,I. Batinic-Haberle, Manganese superoxide dismutase, MnSOD and its mimics, Bio-chim. Biophys. Acta 1822 (2012) 794–814.
[90] F. Zhang, W. Gu, M.E. Hurles, J.R. Lupski, Copy number variation in human health,disease, and evolution, Annu. Rev. Genomics Hum. Genet. 10 (2009) 451–481.
[91] D.G. Wang, J.B. Fan, C.J. Siao, A. Berno, P. Young, R. Sapolsky, G. Ghandour,N. Perkins, E. Winchester, J. Spencer, L. Kruglyak, L. Stein, L. Hsie,T. Topaloglou, E. Hubbell, E. Robinson, M. Mittmann, M.S. Morris, N. Shen,D. Kilburn, J. Rioux, C. Nusbaum, S. Rozen, T.J. Hudson, R. Lipshutz,M. Chee, E.S. Lander, Large-scale identification, mapping, and genotyping ofsingle-nucleotide polymorphisms in the human genome, Science 280 (1998)1077–1082.
[92] S. Sunyaev, V. Ramensky, P. Bork, Towards a structural basis of human non-synonymous single nucleotide polymorphisms, Trends Genet. 16 (2000) 198–200.
[93] A. Crawford, R.G. Fassett, D.P. Geraghty, D.A. Kunde, M.J. Ball, I.K. Robertson,J.S. Coombes, Relationships between single nucleotide polymorphisms of antioxidantenzymes and disease, Gene 501 (2012) 89–103.
[94] L. Forsberg, U. de Faire, R. Morgenstern, Oxidative stress, human genetic variation,and disease, Arch. Biochem. Biophys. 389 (2001) 84–93.
[95] E. Dawson, SNP maps: more markers needed? Mol. Med. Today 5 (1999) 419–420.[96] G. Ravn-Haren, A. Olsen, A. Tjonneland, L.O. Dragsted, B.A. Nexo, H. Wallin,
K. Overvad, O. Raaschou-Nielsen, U. Vogel, Associations between GPX1Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breastcancer risk in a prospective cohort study, Carcinogenesis 27 (2006) 820–825.
[97] T.J. Lightfoot, C.F. Skibola, A.G. Smith, M.S. Forrest, P.J. Adamson, G.J. Morgan,P.M. Bracci, E. Roman, M.T. Smith, E.A. Holly, Polymorphisms in the oxidativestress genes, superoxide dismutase, glutathione peroxidase and catalase and risk ofnon-Hodgkin’s lymphoma, Haematologica 91 (2006) 1222–1227.
[98] A. Bag, N. Bag, Target sequence polymorphism of human manganese superoxidedismutase gene and its association with cancer risk: a review, Cancer Epidemiol.Biomarkers Prev. 17 (2008) 3298–3305.
[99] Y.S. Ho, J.D. Crapo, Isolation and characterization of complementary DNAs encodinghuman manganese-containing superoxide dismutase, FEBS Lett. 229 (1988) 256–260.
[100] S. Shimoda-Matsubayashi, H. Matsumine, T. Kobayashi, Y. Nakagawa-Hattori,Y. Shimizu, Y. Mizuno, Structural dimorphism in the mitochondrial targetingsequence in the human manganese superoxide dismutase gene. A predictive evidencefor conformational change to influence mitochondrial transport and a study of allelicassociation in Parkinson’s disease, Biochem. Biophys. Res. Commun. 226 (1996)561–565.
[101] G. Bresciani, I.B. da Cruz, J.A. de Paz, M.J. Cuevas, J. Gonzalez-Gallego, TheMnSOD Ala16Val SNP: relevance to human diseases and interaction with environ-mental factors, Free Radic. Res. 47 (2013) 781–792.
[102] A.K. Holley, S.K. Dhar, Y. Xu, D.K. St Clair, Manganese superoxide dismutase:beyond life and death, Amino Acids 42 (2012) 139–158.
119Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
[103] A. Sutton, H. Khoury, C. Prip-Buus, C. Cepanec, D. Pessayre, F. Degoul, TheAla16Val genetic dimorphism modulates the import of human manganese superoxidedismutase into rat liver mitochondria, Pharmacogenetics 13 (2003) 145–157.
[104] J.N. Keller, M.S. Kindy, F.W. Holtsberg, D.K. St Clair, H.C. Yen, A. Germeyer,S.M. Steiner, A.J. Bruce-Keller, J.B. Hutchins, M.P. Mattson, Mitochondrial manga-nese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury:suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dys-function, J. Neurosci. 18 (1998) 687–697.
[105] X. Shen, S. Zheng, N.S. Metreveli, P.N. Epstein, Protection of cardiac mitochondriaby overexpression of MnSOD reduces diabetic cardiomyopathy, Diabetes 55 (2006)798–805.
[106] V. Fernandez, G. Tapia, P. Varela, I. Castillo, C. Mora, F. Moya, M. Orellana,L.A. Videla, Redox up-regulated expression of rat liver manganese superoxide dis-mutase and Bcl-2 by thyroid hormone is associated with inhibitor of kappaB-alphaphosphorylation and nuclear factor-kappaB activation, J. Endocrinol. 186 (2005)539–547.
[107] L.L. Ji, Modulation of skeletal muscle antioxidant defense by exercise: role of redoxsignaling, Free Radic. Biol. Med. 44 (2008) 142–152.
[108] L. Goth, A new type of inherited catalase deficiencies: its characterization and com-parison to the Japanese and Swiss type of acatalasemia, Blood Cells Mol. Dis.27 (2001) 512–517.
[109] J.P. French, K.L. Hamilton, J.C. Quindry, Y. Lee, P.A. Upchurch, S.K. Powers,Exercise-induced protection against myocardial apoptosis and necrosis: MnSOD,calcium-handling proteins, and calpain, FASEB J. 22 (2008) 2862–2871.
[110] M. Kanwar, P.S. Chan, T.S. Kern, R.A. Kowluru, Oxidative damage in the retinalmitochondria of diabetic mice: possible protection by superoxide dismutase, Invest.Ophthalmol. Vis. Sci. 48 (2007) 3805–3811.
[111] H. Goto, T. Nishikawa, K. Sonoda, T. Kondo, D. Kukidome, K. Fujisawa,T. Yamashiro, H. Motoshima, T. Matsumura, K. Tsuruzoe, E. Araki, EndothelialMnSOD overexpression prevents retinal VEGF expression in diabetic mice, Biochem.Biophys. Res. Commun. 366 (2008) 814–820.
[112] P.I. Moreira, X. Zhu, X. Wang, H.G. Lee, A. Nunomura, R.B. Petersen, G. Perry,M.A. Smith, Mitochondria: a therapeutic target in neurodegeneration, Biochim.Biophys. Acta 1802 (2010) 212–220.
[113] B. Uttara, A.V. Singh, P. Zamboni, R.T. Mahajan, Oxidative stress and neurodegen-erative diseases: a review of upstream and downstream antioxidant therapeutic options,Curr. Neuropharmacol. 7 (2009) 65–74.
[114] D. Safiulina, A. Kaasik, Energetic and dynamic: how mitochondria meet neuronalenergy demands, PLoS Biol. 11 (2013) e1001755.
[115] J.M. Flynn, S. Melov, SOD2 in mitochondrial dysfunction and neurodegeneration,Free Radic. Biol. Med. 62 (2013) 4–12.
[116] Y. Zhao, B. Zhao, Oxidative stress and the pathogenesis of Alzheimer’s disease, Oxid.Med. Cell. Longev. 2013 (2013) 316523.
[117] M. Padurariu, A. Ciobica, R. Lefter, I.L. Serban, C. Stefanescu, R. Chirita, The oxi-dative stress hypothesis in Alzheimer’s disease, Psychiatr. Danub. 25 (2013) 401–409.
[118] G.E. Crichton, J. Bryan, K.J. Murphy, Dietary antioxidants, cognitive function anddementia—a systematic review, Plant Foods Hum. Nutr. 68 (2013) 279–292.
[119] M.E. De Leo, S. Borrello, M. Passantino, B. Palazzotti, A. Mordente, A. Daniele,V. Filippini, T. Galeotti, C. Masullo, Oxidative stress and overexpression of manga-nese superoxide dismutase in patients with Alzheimer’s disease, Neurosci. Lett.250 (1998) 173–176.
120 Guilherme Bresciani et al.
Author's personal copy
[120] A.M. Swomley, S. Forster, J.T. Keeney, J. Triplett, Z. Zhang, R. Sultana,D.A. Butterfield, Abeta, oxidative stress in Alzheimer disease: evidence based on pro-teomics studies, Biochim. Biophys. Acta 1842 (2013) 1248–1257.
[121] M.A. Ansari, S.W. Scheff, NADPH-oxidase activation and cognition in Alzheimerdisease progression, Free Radic. Biol. Med. 51 (2011) 171–178.
[122] F.X. Guix, T. Wahle, K. Vennekens, A. Snellinx, L. Chavez-Gutierrez, G. Ill-Raga,E. Ramos-Fernandez, C. Guardia-Laguarta, A. Lleo, M. Arimon, O. Berezovska,F.J. Munoz, C.G. Dotti, B. De Strooper, Modification of gamma-secretase bynitrosative stress links neuronal ageing to sporadic Alzheimer’s disease, EMBO Mol.Med. 4 (2012) 660–673.
[123] M.A. Greenough, J. Camakaris, A.I. Bush, Metal dyshomeostasis and oxidative stressin Alzheimer’s disease, Neurochem. Int. 62 (2013) 540–555.
[124] K. Jomova, D. Vondrakova, M. Lawson, M. Valko, Metals, oxidative stress and neu-rodegenerative disorders, Mol. Cell. Biochem. 345 (2010) 91–104.
[125] H.W. Wiener, R.T. Perry, Z. Chen, L.E. Harrell, R.C. Go, A polymorphism inSOD2 is associated with development of Alzheimer’s disease, Genes Brain Behav.6 (2007) 770–775.
[126] G.S. Hong, R. Heun, F. Jessen, J. Popp, F. Hentschel, P. Kelemen, A. Schulz,W. Maier, H. Kolsch, Gene variations in GSTM3 are a risk factor for Alzheimer’s dis-ease, Neurobiol. Aging 30 (2009) 691–696.
[127] O.C. Maes, H.M. Schipper, G. Chong, H.M. Chertkow, E. Wang, A GSTM3 poly-morphism associated with an etiopathogenetic mechanism in Alzheimer disease, Neu-robiol. Aging 31 (2010) 34–45.
[128] O. Hwang, Role of oxidative stress in Parkinson’s disease, Exp. Neurobiol. 22 (2013)11–17.
[129] H. Yamaguchi, J. Shen, Absence of dopaminergic neuronal degeneration and oxida-tive damage in aged DJ-1-deficient mice, Mol. Neurodegener. 2 (2007) 10.
[130] E. Andres-Mateos, C. Perier, L. Zhang, B. Blanchard-Fillion, T.M. Greco,B. Thomas, H.S. Ko, M. Sasaki, H. Ischiropoulos, S. Przedborski, T.M. Dawson,V.L. Dawson, DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-likeperoxidase, Proc. Natl. Acad. Sci. U.S.A 104 (2007) 14807–14812.
[131] H. Koh, H. Kim, M.J. Kim, J. Park, H.J. Lee, J. Chung, Silent information regulator 2(Sir2) and Forkhead box O (FOXO) complement mitochondrial dysfunction anddopaminergic neuron loss in Drosophila PTEN-induced kinase 1 (PINK1) nullmutant, J. Biol. Chem. 287 (2012) 12750–12758.
[132] V. Wang, S.Y. Chen, T.C. Chuang, D.E. Shan, B.W. Soong, M.C. Kao, Val–9Alaand Ile+58Thr polymorphism of MnSOD in Parkinson’s disease, Clin. Biochem.43 (2010) 979–982.
[133] M. Singh, A.J. Khan, P.P. Shah, R. Shukla, V.K. Khanna, D. Parmar, Polymorphismin environment responsive genes and association with Parkinson disease, Mol. Cell.Biochem. 312 (2008) 131–138.
[134] E.M. Grasbon-Frodl, S. Kosel, O. Riess, U. Muller, P. Mehraein, M.B. Graeber,Analysis of mitochondrial targeting sequence and coding region polymorphisms ofthe manganese superoxide dismutase gene in German Parkinson disease patients, Bio-chem. Biophys. Res. Commun. 255 (1999) 749–752.
[135] C.S. Fong, R.M.Wu, J.C. Shieh, Y.T. Chao, Y.P. Fu, C.L. Kuao, C.W. Cheng, Pes-ticide exposure on southwestern Taiwanese withMnSOD andNQO1 polymorphismsis associated with increased risk of Parkinson’s disease, Clin. Chim. Acta 378 (2007)136–141.
[136] M.A. Moskowitz, E.H. Lo, C. Iadecola, The science of stroke: mechanisms in searchof treatments, Neuron 67 (2010) 181–198.
121Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
[137] H. Jaffer, V.B. Morris, D. Stewart, V. Labhasetwar, Advances in stroke therapy, DrugDeliv. Transl. Res. 1 (2011) 409–419.
[138] S.L. Mehta, Y. Lin, W. Chen, F. Yu, L. Cao, Q. He, P.H. Chan, P.A. Li, Manganesesuperoxide dismutase deficiency exacerbates ischemic brain damage under hypergly-cemic conditions by altering autophagy, Transl. Stroke Res. 2 (2011) 42–50.
[139] H.F. Huang, F. Guo, Y.Z. Cao, W. Shi, Q. Xia, Neuroprotection by manganesesuperoxide dismutase (MnSOD) mimics: antioxidant effect and oxidative stress regu-lation in acute experimental stroke, CNS Neurosci. Ther. 18 (2012) 811–818.
[140] A.V. Rao, B. Balachandran, Role of oxidative stress and antioxidants in neurodegen-erative diseases, Nutr. Neurosci. 5 (2002) 291–309.
[141] J.K. Yao, R.D. Reddy, D.P. van Kammen, Oxidative damage and schizophrenia: anoverview of the evidence and its therapeutic implications, CNS Drugs 15 (2001)287–310.
[142] Y. Melamed, P. Sirota, D.R. Dicker, P. Fishman, Superoxide anion production byneutrophils derived from peripheral blood of schizophrenic patients, PsychiatryRes. 77 (1998) 29–34.
[143] P. Sirota, R. Gavrieli, B. Wolach, Overproduction of neutrophil radical oxygen spe-cies correlates with negative symptoms in schizophrenic patients: parallel studies onneutrophil chemotaxis, superoxide production and bactericidal activity, PsychiatryRes. 121 (2003) 123–132.
[144] J. Flatow, P. Buckley, B.J. Miller, Meta-analysis of oxidative stress in schizophrenia,Biol. Psychiatry 74 (2013) 400–409.
[145] M.C. Tsai, C.W. Liou, T.K. Lin, I.M. Lin, T.L. Huang, Changes in oxidative stressmarkers in patients with schizophrenia: the effect of antipsychotic drugs, PsychiatryRes. 209 (2013) 284–290.
[146] X.Y. Zhang, C. Chen da, M.H. Xiu, F.D. Yang, Y. Tan, X. Luo, L. Zuo,T.A. Kosten, T.R. Kosten, Cognitive function, plasmaMnSOD activity, andMnSODAla–9Val polymorphism in patients with schizophrenia and normal controls,Schizophr. Bull. 40 (2014) 592–601.
[147] L.J. Greenlund, T.L. Deckwerth, E.M. Johnson Jr., Superoxide dismutase delays neu-ronal apoptosis: a role for reactive oxygen species in programmed neuronal death,Neuron 14 (1995) 303–315.
[148] C. Song, A.A. Killeen, B.E. Leonard, Catalase, superoxide dismutase and glutathioneperoxidase activity in neutrophils of sham-operated and olfactory-bulbectomised rats fol-lowing chronic treatment with desipramine and lithium chloride, Neuropsychobiology30 (1994) 24–28.
[149] H. Xu, C. Luo, J.S. Richardson, X.M. Li, Recovery of hippocampal cell proliferationand BDNF levels, both of which are reduced by repeated restraint stress, is acceleratedby chronic venlafaxine, Pharmacogenomics J. 4 (2004) 322–331.
[150] A. Sarandol, E. Sarandol, S.S. Eker, S. Erdinc, E. Vatansever, S. Kirli, Major depressivedisorder is accompanied with oxidative stress: short-term antidepressant treatment doesnot alter oxidative–antioxidative systems, Hum. Psychopharmacol. 22 (2007) 67–73.
[151] S. Selek, H.A. Savas, H.S. Gergerlioglu, F. Bulbul, E. Uz, M. Yumru, The course ofnitric oxide and superoxide dismutase during treatment of bipolar depressive episode,J. Affect. Disord. 107 (2008) 89–94.
[152] P. Galecki, J. Smigielski, A. Florkowski, K. Bobinska, T. Pietras, J. Szemraj, Analysis oftwo polymorphisms of the manganese superoxide dismutase gene (Ile–58Thr and Ala–9Val) in patients with recurrent depressive disorder, Psychiatry Res. 179 (2010) 43–46.
[153] B.E. Cumurcu, H. Ozyurt, O. Ates, I.G. Gul, S. Demir, R. Karlidag, Analysis of man-ganese superoxide dismutase (MnSOD: Ala–9Val) and glutathione peroxidase (GSH-Px: Pro 197 Leu) gene polymorphisms in mood disorders, Bosn. J. Basic Med. Sci.13 (2013) 109–113.
122 Guilherme Bresciani et al.
Author's personal copy
[154] A. Mansouri, A. Tarhuni, I. Larosche, F. Reyl-Desmars, C. Demeilliers, F. Degoul,P. Nahon, A. Sutton, R. Moreau, B. Fromenty, D. Pessayre, MnSOD over-expression prevents liver mitochondrial DNA depletion after an alcohol binge butworsens this effect after prolonged alcohol consumption in mice, Dig. Dis.28 (2010) 756–775.
[155] M. Parola, G. Robino, Oxidative stress-related molecules and liver fibrosis, J. Hepatol.35 (2001) 297–306.
[156] P. Letteron, V. Duchatelle, A. Berson, B. Fromenty, C. Fisch, C. Degott,J.P. Benhamou, D. Pessayre, Increased ethane exhalation, an in vivo index of lipid per-oxidation, in alcohol-abusers, Gut 34 (1993) 409–414.
[157] P. Letteron, B. Fromenty, B. Terris, C. Degott, D. Pessayre, Acute and chronic hepaticsteatosis lead to in vivo lipid peroxidation in mice, J. Hepatol. 24 (1996) 200–208.
[158] I. Emerit, F. Serejo, P. Filipe, A. Alaoui Youssefi, A. Fernandes, A. Costa, J. Freitas,F. Ramalho, A. Baptista, M. Carneiro de Moura, Clastogenic factors as biomarkers ofoxidative stress in chronic hepatitis C, Digestion 62 (2000) 200–207.
[159] S.K. Jain, P.W. Pemberton, A. Smith, R.F.McMahon, P.C. Burrows, A. Aboutwerat,T.W. Warnes, Oxidative stress in chronic hepatitis C: not just a feature of late stagedisease, J. Hepatol. 36 (2002) 805–811.
[160] S.J. Cotler, E. Kallwitz, V. TenCate, A. Bhushan, J. Berkes, E. Benedetti, J. Layden-Almer, T.J. Layden, T. Valyi-Nagy, G. Guzman, Diabetes and hepatic oxidative dam-age are associated with hepatitis C progression after liver transplantation,Transplantation 84 (2007) 587–591.
[161] M. Valgimigli, L. Valgimigli, D. Trere, S. Gaiani, G.F. Pedulli, L. Gramantieri,L. Bolondi, Oxidative stress EPR measurement in human liver by radical-probe tech-nique. Correlation with etiology, histology and cell proliferation, Free Radic. Res.36 (2002) 939–948.
[162] A. Bhargava, G.V. Raghuram, N. Pathak, S. Varshney, S.K. Jatawa, D. Jain,P.K. Mishra, Occult hepatitis C virus elicits mitochondrial oxidative stress in lympho-cytes and triggers PI3-kinase-mediated DNA damage response, Free Radic. Biol.Med.51 (2011) 1806–1814.
[163] F. Capone, E. Guerriero, A. Sorice, P. Maio, G. Colonna, G. Castello, S. Costantini,Characterization of metalloproteinases, oxidative status and inflammation levels in thedifferent stages of fibrosis in HCV patients, Clin. Biochem. 45 (2012) 525–529.
[164] U.A. Boelsterli, P.L. Lim, Mitochondrial abnormalities—a link to idiosyncratic drughepatotoxicity? Toxicol. Appl. Pharmacol. 220 (2007) 92–107.
[165] K. Wang, Molecular mechanisms of hepatic apoptosis, Cell Death Dis. 5 (2014) e996.[166] M. van Gurp, N. Festjens, G. van Loo, X. Saelens, P. Vandenabeele, Mitochondrial
intermembrane proteins in cell death, Biochem. Biophys. Res. Commun. 304 (2003)487–497.
[167] X. Saelens, N. Festjens, L. Vande Walle, M. van Gurp, G. van Loo, P. Vandenabeele,Toxic proteins released from mitochondria in cell death, Oncogene 23 (2004)2861–2874.
[168] C. Garrido, L. Galluzzi, M. Brunet, P.E. Puig, C. Didelot, G. Kroemer, Mechanismsof cytochrome c release from mitochondria, Cell Death Differ. 13 (2006) 1423–1433.
[169] M.F. Chen, L.R. Mo, R.C. Lin, J.Y. Kuo, K.K. Chang, C. Liao, F.J. Lu, Increase ofresting levels of superoxide anion in the whole blood of patients with decompensatedliver cirrhosis, Free Radic. Biol. Med. 23 (1997) 672–679.
[170] N.G. Westman, S.L. Marklund, Copper- and zinc-containing superoxide dismutaseand manganese-containing superoxide dismutase in human tissues and human malig-nant tumors, Cancer Res. 41 (1981) 2962–2966.
[171] I. Qadri, M. Iwahashi, J.M. Capasso, M.W. Hopken, S. Flores, J. Schaack,F.R. Simon, Induced oxidative stress and activated expression of manganese
123Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
superoxide dismutase during hepatitis C virus replication: role of JNK, p38MAPK andAP-1, Biochem. J. 378 (2004) 919–928.
[172] C. Clemente, S. Elba, G. Buongiorno, V. Guerra, B. D’Attoma, A. Orlando, F. Russo,Manganese superoxide dismutase activity and incidence of hepatocellular carcinoma inpatients with Child-Pugh class A liver cirrhosis: a 7-year follow-up study, Liver Int.27 (2007) 791–797.
[173] T. Tamai, H. Uto, Y. Takami, K. Oda, A. Saishoji, M. Hashiguchi, K. Kumagai,T. Kure, S. Mawatari, A. Moriuchi, M. Oketani, A. Ido, H. Tsubouchi, Serum man-ganese superoxide dismutase and thioredoxin are potential prognostic markers for hep-atitis C virus-related hepatocellular carcinoma, World J. Gastroenterol. 17 (2011)4890–4898.
[174] G. Fortunato, G. Castaldo, G. Oriani, R. Cerini, M. Intrieri, E. Molinaro, I. Gentile,G. Borgia, M. Piazza, F. Salvatore, L. Sacchetti, Multivariate discriminant functionbased on six biochemical markers in blood can predict the cirrhotic evolution ofchronic hepatitis, Clin. Chem. 47 (2001) 1696–1700.
[175] O.R. Koch, M.E. De Leo, S. Borrello, G. Palombini, T. Galeotti, Ethanol treatmentup-regulates the expression of mitochondrial manganese superoxide dismutase in ratliver, Biochem. Biophys. Res. Commun. 201 (1994) 1356–1365.
[176] S.I. Liochev, I. Fridovich, The effects of superoxide dismutase on H2O2 formation,Free Radic. Biol. Med. 42 (2007) 1465–1469.
[177] S.E. McKim, E. Gabele, F. Isayama, J.C. Lambert, L.M. Tucker, M.D. Wheeler,H.D. Connor, R.P. Mason, M.A. Doll, D.W. Hein, G.E. Arteel, Inducible nitricoxide synthase is required in alcohol-induced liver injury: studies with knockout mice,Gastroenterology 125 (2003) 1834–1844.
[178] M. Thirunavukkarasu, S.V. Penumathsa, S. Koneru, B. Juhasz, L. Zhan, H. Otani,D. Bagchi, D.K. Das, N. Maulik, Resveratrol alleviates cardiac dysfunction instreptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and hemeoxygenase, Free Radic. Biol. Med. 43 (2007) 720–729.
[179] R.A. Kowluru, L. Atasi, Y.S. Ho, Role of mitochondrial superoxide dismutase in thedevelopment of diabetic retinopathy, Invest. Ophthalmol. Vis. Sci. 47 (2006)1594–1599.
[180] A. Naudi, M. Jove, V. Ayala, A. Cassanye, J. Serrano, H. Gonzalo, J. Boada, J. Prat,M. Portero-Otin, R. Pamplona, Cellular dysfunction in diabetes as maladaptiveresponse to mitochondrial oxidative stress, Exp. Diabetes Res. 2012 (2012) 696215.
[181] M. Brownlee, The pathobiology of diabetic complications: a unifying mechanism,Diabetes 54 (2005) 1615–1625.
[182] V. Ostrow, S. Wu, A. Aguilar, R. Bonner Jr., E. Suarez, F. De Luca, Associationbetween oxidative stress and masked hypertension in a multi-ethnic population ofobese children and adolescents, J. Pediatr. 158 (2011), 628–633 e621.
[183] D. Molnar, T. Decsi, B. Koletzko, Reduced antioxidant status in obese children withmultimetabolic syndrome, Int. J. Obes. Relat. Metab. Disord. 28 (2004) 1197–1202.
[184] Y.G. Zhu, S.M. Zhang, J.Y. Wang, W.Q. Xiao, X.Y. Wang, J.F. Zhou, Overweightand obesity-induced oxidative stress in children, Biomed. Environ. Sci. 19 (2006)353–359.
[185] N. Schauble, K. Reichwald, W. Grassl, H. Bechstein, H.C. Muller, A. Scherag,F. Geller, M. Utting, W. Siegfried, H. Goldschmidt, J. Blundell, C. Lawton,R. Alam, S. Whybrow, J. Stubbs, M. Platzer, J. Hebebrand, A. Hinney, Humangalanin (GAL) and galanin 1 receptor (GALR1) variations are not involved in fat intakeand early onset obesity, J. Nutr. 135 (2005) 1387–1392.
[186] T. Nomiyama, Y. Tanaka, L. Piao, K. Nagasaka, K. Sakai, T. Ogihara, K. Nakajima,H. Watada, R. Kawamori, The polymorphism of manganese superoxide dismutase isassociated with diabetic nephropathy in Japanese type 2 diabetic patients, J. Hum.Genet. 48 (2003) 138–141.
124 Guilherme Bresciani et al.
Author's personal copy
[187] A. Mollsten, A. Jorsal, M. Lajer, N. Vionnet, L. Tarnow, The V16A polymorphism inSOD2 is associated with increased risk of diabetic nephropathy and cardiovascular dis-ease in type 1 diabetes, Diabetologia 52 (2009) 2590–2593.
[188] A. Mollsten, S.L. Marklund, M.Wessman, M. Svensson, C. Forsblom,M. Parkkonen,K. Brismar, P.H. Groop, G. Dahlquist, A functional polymorphism in the manganesesuperoxide dismutase gene and diabetic nephropathy, Diabetes 56 (2007) 265–269.
[189] I.A. Strokov, T.R. Bursa, O.I. Drepa, E.V. Zotova, V.V. Nosikov, A.S. Ametov,Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabe-tes: a population-based case–control study, Acta Diabetol. 40 (Suppl. 2) (2003)S375–S379.
[190] T. Hovnik, V. Dolzan, N.U. Bratina, K.T. Podkrajsek, T. Battelino, Genetic poly-morphisms in genes encoding antioxidant enzymes are associated with diabetic reti-nopathy in type 1 diabetes, Diabetes Care 32 (2009) 2258–2262.
[191] T. Kangas-Kontio, S. Vavuli, S.J. Kakko, J. Penna, E.R. Savolainen, M.J. Savolainen,M.J. Liinamaa, Polymorphism of the manganese superoxide dismutase gene but not ofvascular endothelial growth factor gene is a risk factor for diabetic retinopathy, Br. J.Ophthalmol. 93 (2009) 1401–1406.
[192] M. Flekac, J. Skrha, J. Hilgertova, Z. Lacinova, M. Jarolimkova, Gene polymor-phisms of superoxide dismutases and catalase in diabetes mellitus, BMCMed. Genet.9 (2008) 30.
[193] H. Chen,M. Yu,M. Li, R. Zhao, Q. Zhu,W. Zhou,M. Lu, Y. Lu, T. Zheng, J. Jiang,W. Zhao, K. Xiang, W. Jia, L. Liu, Polymorphic variations in manganese superoxidedismutase (MnSOD), glutathione peroxidase-1 (GPX1), and catalase (CAT) contrib-ute to elevated plasma triglyceride levels in Chinese patients with type 2 diabetes ordiabetic cardiovascular disease, Mol. Cell. Biochem. 363 (2012) 85–91.
[194] M.M. Duarte, R.N. Moresco, T. Duarte, A. Santi, M.D. Bagatini, I.B. da Cruz,M.R. Schetinger, V.L. Loro, Oxidative stress in hypercholesterolemia and its associ-ation with Ala16Val superoxide dismutase gene polymorphism, Clin. Biochem.43 (2010) 1118–1123.
[195] M.A. Montano, J.P. Barrio Lera, M.G. Gottlieb, C.H. Schwanke, M.I. da Rocha,M.F. Manica-Cattani, G.F. dos Santos, I.B. da Cruz, Association between manganesesuperoxide dismutase (MnSOD) gene polymorphism and elderly obesity, Mol. Cell.Biochem. 328 (2009) 33–40.
[196] M.G. Gottlieb, C.H. Schwanke, A.F. Santos, P.F. Jobim, D.P. Mussel, I.B. da Cruz,Association among oxidized LDL levels, MnSOD, apolipoprotein E polymorphisms,and cardiovascular risk factors in a south Brazilian region population, Genet. Mol. Res.4 (2005) 691–703.
[197] M.A. Montano, I.B. da Cruz, M.M. Duarte, C. Krewer Cda, M.I. da Rocha,M.F. Manica-Cattani, F.A. Soares, G. Rosa, A.F. Maris, F.G. Battiston, A. Trott,J.P. Lera, Inflammatory cytokines in vitro production are associated with Ala16Valsuperoxide dismutase gene polymorphism of peripheral blood mononuclear cells,Cytokine 60 (2012) 30–33.
[198] T. Fukai, M. Ushio-Fukai, Superoxide dismutases: role in redox signaling, vascularfunction, and diseases, Antioxid. Redox Signal. 15 (2011) 1583–1606.
[199] M.C. Gongora, Z. Qin, K. Laude, H.W. Kim, L. McCann, J.R. Folz, S. Dikalov,T. Fukai, D.G. Harrison, Role of extracellular superoxide dismutase in hypertension,Hypertension 48 (2006) 473–481.
[200] S. Dieterich, U. Bieligk, K. Beulich, G. Hasenfuss, J. Prestle, Gene expression ofantioxidative enzymes in the human heart: increased expression of catalase in theend-stage failing heart, Circulation 101 (2000) 33–39.
[201] J.J. Wen, G. Vyatkina, N. Garg, Oxidative damage during chagasic cardiomyopathydevelopment: role of mitochondrial oxidant release and inefficient antioxidant defense,Free Radic. Biol. Med. 37 (2004) 1821–1833.
125Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
[202] A. Tedgui, Z. Mallat, Cytokines in atherosclerosis: pathogenic and regulatory path-ways, Physiol. Rev. 86 (2006) 515–581.
[203] S.L. Kardia, M.T. Greene, E. Boerwinkle, S.T. Turner, I.J. Kullo, Investigating thecomplex genetic architecture of ankle-brachial index, a measure of peripheral arterialdisease, in non-Hispanic whites, BMC Med. Genomics 1 (2008) 16.
[204] C. Kunsch, R.M. Medford, Oxidative stress as a regulator of gene expression in thevasculature, Circ. Res. 85 (1999) 753–766.
[205] L.Y. Wing, Y.C. Chen, Y.Y. Shih, J.C. Cheng, Y.J. Lin, M.J. Jiang, Effects of oralestrogen on aortic ROS-generating and -scavenging enzymes and atherosclerosis inapoE-deficient mice, Exp. Biol. Med. (Maywood) 234 (2009) 1037–1046.
[206] J.A. Araujo, M. Zhang, F. Yin, Heme oxygenase-1, oxidation, inflammation, and ath-erosclerosis, Front. Pharmacol. 3 (2012) 119.
[207] S. Kakko, M. Paivansalo, P. Koistinen, Y.A. Kesaniemi, V.L. Kinnula,M.J. Savolainen, The signal sequence polymorphism of the MnSOD gene is associatedwith the degree of carotid atherosclerosis, Atherosclerosis 168 (2003) 147–152.
[208] X.M. Yuan, W. Li, U.T. Brunk, H. Dalen, Y.H. Chang, A. Sevanian, Lysosomaldestabilization during macrophage damage induced by cholesterol oxidation products,Free Radic. Biol. Med. 28 (2000) 208–218.
[209] S.W. Ballinger, C. Patterson, C.A. Knight-Lozano, D.L. Burow, C.A. Conklin,Z. Hu, J. Reuf, C. Horaist, R. Lebovitz, G.C. Hunter, K. McIntyre, M.S. Runge,Mitochondrial integrity and function in atherogenesis, Circulation 106 (2002)544–549.
[210] Y. Li, T.T. Huang, E.J. Carlson, S. Melov, P.C. Ursell, J.L. Olson, L.J. Noble,M.P. Yoshimura, C. Berger, P.H. Chan, D.C. Wallace, C.J. Epstein, Dilated cardio-myopathy and neonatal lethality in mutant mice lacking manganese superoxide dis-mutase, Nat. Genet. 11 (1995) 376–381.
[211] S. Melov, J.A. Schneider, B.J. Day, D. Hinerfeld, P. Coskun, S.S. Mirra, J.D. Crapo,D.C. Wallace, A novel neurological phenotype in mice lacking mitochondrial man-ganese superoxide dismutase, Nat. Genet. 18 (1998) 159–163.
[212] S. Melov, S.R. Doctrow, J.A. Schneider, J. Haberson, M. Patel, P.E. Coskun,K. Huffman, D.C. Wallace, B. Malfroy, Lifespan extension and rescue of spongiformencephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxidedismutase–catalase mimetics, J. Neurosci. 21 (2001) 8348–8353.
[213] S. Melov, P. Coskun, M. Patel, R. Tuinstra, B. Cottrell, A.S. Jun, T.H. Zastawny,M. Dizdaroglu, S.I. Goodman, T.T. Huang, H. Miziorko, C.J. Epstein,D.C. Wallace, Mitochondrial disease in superoxide dismutase 2 mutant mice, Proc.Natl. Acad. Sci. U.S.A 96 (1999) 846–851.
[214] M.C. Zimmerman, E. Lazartigues, J.A. Lang, P. Sinnayah, I.M. Ahmad, D.R. Spitz,R.L. Davisson, Superoxide mediates the actions of angiotensin II in the central nervoussystem, Circ. Res. 91 (2002) 1038–1045.
[215] A.E. Dikalova, A.T. Bikineyeva, K. Budzyn, R.R. Nazarewicz, L. McCann,W. Lewis, D.G. Harrison, S.I. Dikalov, Therapeutic targeting of mitochondrial super-oxide in hypertension, Circ. Res. 107 (2010) 106–116.
[216] S.L. Archer, G. Marsboom, G.H. Kim, H.J. Zhang, P.T. Toth, E.C. Svensson,J.R. Dyck, M. Gomberg-Maitland, B. Thebaud, A.N. Husain, N. Cipriani,J. Rehman, Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmo-nary arterial hypertension: a basis for excessive cell proliferation and a new therapeutictarget, Circulation 121 (2010) 2661–2671.
[217] K.M. Connor, S. Subbaram, K.J. Regan, K.K. Nelson, J.E. Mazurkiewicz,P.J. Bartholomew, A.E. Aplin, Y.T. Tai, J. Aguirre-Ghiso, S.C. Flores,J.A. Melendez, Mitochondrial H2O2 regulates the angiogenic phenotype via PTENoxidation, J. Biol. Chem. 280 (2005) 16916–16924.
126 Guilherme Bresciani et al.
Author's personal copy
[218] M.R. Abid, J.C. Tsai, K.C. Spokes, S.S. Deshpande, K. Irani, W.C. Aird, Vascularendothelial growth factor induces manganese-superoxide dismutase expression inendothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism,FASEB J. 15 (2001) 2548–2550.
[219] F.M. Alameddine, A.M. Zafari, Genetic polymorphisms and oxidative stress in heartfailure, Congest. Heart Fail. 8 (2002) 157–164, 172.
[220] M.M. Givertz, W.S. Colucci, New targets for heart-failure therapy: endothelin,inflammatory cytokines, and oxidative stress, Lancet 352 (Suppl. 1) (1998) SI34–SI38.
[221] Z. Mallat, I. Philip, M. Lebret, D. Chatel, J. Maclouf, A. Tedgui, Elevated levels of8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potentialrole for in vivo oxidant stress in ventricular dilatation and progression to heart failure,Circulation 97 (1998) 1536–1539.
[222] C.R. Diaz-Velez, S. Garcia-Castineiras, E. Mendoza-Ramos, E. Hernandez-Lopez,Increased malondialdehyde in peripheral blood of patients with congestive heart fail-ure, Am. Heart J. 131 (1996) 146–152.
[223] M. Keith, A. Geranmayegan, M.J. Sole, R. Kurian, A. Robinson, A.S. Omran,K.N. Jeejeebhoy, Increased oxidative stress in patients with congestive heart failure,J. Am. Coll. Cardiol. 31 (1998) 1352–1356.
[224] Y.M. Hsueh, P. Lin, H.W. Chen, H.S. Shiue, C.J. Chung, C.T. Tsai, Y.K. Huang,H.Y. Chiou, C.J. Chen, Genetic polymorphisms of oxidative and antioxidant enzymesand arsenic-related hypertension, J. Toxicol. Environ. Health A 68 (2005) 1471–1484.
[225] H. Fujimoto, J. Taguchi, Y. Imai, S. Ayabe, H. Hashimoto, H. Kobayashi,K. Ogasawara, T. Aizawa, M. Yamakado, R. Nagai, M. Ohno, Manganese superoxidedismutase polymorphism affects the oxidized low-density lipoprotein-induced apo-ptosis of macrophages and coronary artery disease, Eur. Heart J. 29 (2008) 1267–1274.
[226] H. Fujimoto, H. Kobayashi, K. Ogasawara, M. Yamakado, M. Ohno, Association ofthe manganese superoxide dismutase polymorphism with vasospastic angina pectoris,J. Cardiol. 55 (2010) 205–210.
[227] J.C. Charniot, A. Sutton, D. Bonnefont-Rousselot, C. Cosson, R. Khani-Bittar,P. Giral, N. Charnaux, J.P. Albertini, Manganese superoxide dismutase dimorphismrelationship with severity and prognosis in cardiogenic shock due to dilated cardiomy-opathy, Free Radic. Res. 45 (2011) 379–388.
[228] R.P. Young, R. Hopkins, P.N. Black, C. Eddy, L. Wu, G.D. Gamble, G.D. Mills,J.E. Garrett, T.E. Eaton, M.I. Rees, Functional variants of antioxidant genes insmokers with COPD and in those with normal lung function, Thorax 61 (2006)394–399.
[229] J.Y. Choi, M.L. Neuhouser, M. Barnett, M. Hudson, A.R. Kristal, M. Thornquist,I.B. King, G.E. Goodman, C.B. Ambrosone, Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers, CancerEpidemiol. Biomarkers Prev. 16 (2007) 1115–1120.
[230] J. Zejnilovic, N. Akev, H. Yilmaz, T. Isbir, Association between manganese superox-ide dismutase polymorphism and risk of lung cancer, Cancer Genet. Cytogenet.189 (2009) 1–4.
[231] P. Nahon, N. Charnaux, V. Friand, C. Prost-Squarcioni, M. Ziol, N. Lievre,J.C. Trinchet, M. Beaugrand, L. Gattegno, D. Pessayre, A. Sutton, The manganesesuperoxide dismutase Ala16Val dimorphism modulates iron accumulation in humanhepatoma cells, Free Radic. Biol. Med. 45 (2008) 1308–1317.
[232] P. Nahon, A. Sutton, P. Rufat, M. Ziol, H. Akouche, C. Laguillier, N. Charnaux,N. Ganne-Carrie, V. Grando-Lemaire, G. N’Kontchou, J.C. Trinchet,L. Gattegno, D. Pessayre, M. Beaugrand, Myeloperoxidase and superoxide dismutase2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alco-holic cirrhosis, Hepatology 50 (2009) 1484–1493.
127Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
[233] S. Wang, F. Wang, X. Shi, J. Dai, Y. Peng, X. Guo, X. Wang, H. Shen, Z. Hu, Asso-ciation between manganese superoxide dismutase (MnSOD) Val–9Ala polymorphismand cancer risk—a meta-analysis, Eur. J. Cancer 45 (2009) 2874–2881.
[234] J.Y. Choi, M.L. Neuhouser, M.J. Barnett, C.C. Hong, A.R. Kristal,M.D. Thornquist, I.B. King, G.E. Goodman, C.B. Ambrosone, Iron intake, oxidativestress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort,Carcinogenesis 29 (2008) 964–970.
[235] F. Caple, E.A. Williams, A. Spiers, J. Tyson, B. Burtle, A.K. Daly, J.C. Mathers,J.E. Hesketh, Inter-individual variation in DNA damage and base excision repair inyoung, healthy non-smokers: effects of dietary supplementation and genotype, Br.J. Nutr. 103 (2010) 1585–1593.
[236] S. Stroth, K. Hille, M. Spitzer, R. Reinhardt, Aerobic endurance exercise benefitsmemory and affect in young adults, Neuropsychol. Rehabil. 19 (2009) 223–243.
[237] P.R. Nader, R.H. Bradley, R.M. Houts, S.L. McRitchie, M. O’Brien, Moderate-to-vigorous physical activity from ages 9 to 15 years, JAMA 300 (2008) 295–305.
[238] M.C. Polidori, P. Mecocci, A. Cherubini, U. Senin, Physical activity and oxidativestress during aging, Int. J. Sports Med. 21 (2000) 154–157.
[239] T. Fernandes, J.S. Nakamuta, F.C. Magalhaes, F.R. Roque, C. Lavini-Ramos,I.T. Schettert, V. Coelho, J.E. Krieger, E.M. Oliveira, Exercise training restores theendothelial progenitor cells number and function in hypertension: implications forangiogenesis, J. Hypertens. 30 (2012) 2133–2143.
[240] J.A. Blumenthal, M.A. Babyak, C. O’Connor, S. Keteyian, J. Landzberg, J. Howlett,W. Kraus, S. Gottlieb, G. Blackburn, A. Swank, D.J.Whellan, Effects of exercise train-ing on depressive symptoms in patients with chronic heart failure: the HF-ACTIONrandomized trial, JAMA 308 (2012) 465–474.
[241] C. Oliveira, M. Simoes, J. Carvalho, J. Ribeiro, Combined exercise for people withtype 2 diabetes mellitus: a systematic review, Diabetes Res. Clin. Pract. 98 (2012)187–198.
[242] C.L. Davis, N.K. Pollock, J.L. Waller, J.D. Allison, B.A. Dennis, R. Bassali,A. Melendez, C.A. Boyle, B.A. Gower, Exercise dose and diabetes risk in overweightand obese children: a randomized controlled trial, JAMA 308 (2012) 1103–1112.
[243] W.E. Kraus, C.A. Slentz, Exercise training, lipid regulation, and insulin action: a tan-gled web of cause and effect, Obesity (Silver Spring) 17 (Suppl. 3) (2009) S21–S26.
[244] G. Fuchsjager-Mayrl, J. Pleiner, G.F. Wiesinger, A.E. Sieder, M. Quittan, M.J. Nuhr,C. Francesconi, H.P. Seit, M. Francesconi, L. Schmetterer, M. Wolzt, Exercise train-ing improves vascular endothelial function in patients with type 1 diabetes, DiabetesCare 25 (2002) 1795–1801.
[245] N.P. Kadoglou, G. Fotiadis, A. Kapelouzou, A. Kostakis, C.D. Liapis, I.S. Vrabas, Thedifferential anti-inflammatory effects of exercise modalities and their association withearly carotid atherosclerosis progression in patients with type 2 diabetes, Diabet. Med.30 (2013) e41–e50.
[246] D.J. Green, G. O’Driscoll, M.J. Joyner, N.T. Cable, Exercise and cardiovascular riskreduction: time to update the rationale for exercise? J. Appl. Physiol. (1985) 105 (2008)766–768.
[247] F.Dimeo,N.Pagonas, F. Seibert,R.Arndt,W.Zidek,T.H.Westhoff,Aerobic exercisereduces blood pressure in resistant hypertension, Hypertension 60 (2012) 653–658.
[248] D. Hansen, B.O. Eijnde, M. Roelants, T. Broekmans, J.L. Rummens, K. Hensen,A. Daniels, M. Van Erum, K. Bonne, I. Reyckers, T. Alders, J. Berger,P. Dendale, Clinical benefits of the addition of lower extremity low-intensity resis-tance muscle training to early aerobic endurance training intervention in patients withcoronary artery disease: a randomized controlled trial, J. Rehabil. Med. 43 (2011)800–807.
128 Guilherme Bresciani et al.
Author's personal copy
[249] H. Otani, Oxidative stress as pathogenesis of cardiovascular risk associated withmetabolic syndrome, Antioxid. Redox Signal. 15 (2011) 1911–1926.
[250] S.K. Powers, S.L. Lennon, Analysis of cellular responses to free radicals: focus onexercise and skeletal muscle, Proc. Nutr. Soc. 58 (1999) 1025–1033.
[251] E.C. Gomes, A.N. Silva, M.R. de Oliveira, Oxidants, antioxidants, and the beneficialroles of exercise-induced production of reactive species, Oxid. Med. Cell. Longev.2012 (2012) 756132.
[252] S. Ohishi, T. Kizaki, T. Ookawara, K. Toshinai, S. Haga, F. Karasawa, T. Satoh,N. Nagata, L.L. Ji, H. Ohno, The effect of exhaustive exercise on the antioxidantenzyme system in skeletal muscle from calcium-deficient rats, Pflugers Arch.435 (1998) 767–774.
[253] J. Hollander, R. Fiebig, M. Gore, J. Bejma, T. Ookawara, H. Ohno, L.L. Ji, Super-oxide dismutase gene expression in skeletal muscle: fiber-specific adaptation to endur-ance training, Am. J. Physiol. 277 (1999) R856–R862.
[254] J. Hollander, J. Bejma, T. Ookawara, H. Ohno, L.L. Ji, Superoxide dismutase geneexpression in skeletal muscle: fiber-specific effect of age, Mech. Ageing Dev.116 (2000) 33–45.
[255] O. Pansarasa, G. D’Antona, M.R. Gualea, B. Marzani, M.A. Pellegrino, F. Marzatico,“Oxidative stress”: effects of mild endurance training and testosterone treatment on ratgastrocnemius muscle, Eur. J. Appl. Physiol. 87 (2002) 550–555.
[256] T. Ookawara, S. Haga, S. Ha, S. Oh-Ishi, K. Toshinai, T. Kizaki, L.L. Ji, K. Suzuki,H. Ohno, Effects of endurance training on three superoxide dismutase isoenzymes inhuman plasma, Free Radic. Res. 37 (2003) 713–719.
[257] P.J. Adhihetty, T. Taivassalo, R.G. Haller, D.R. Walkinshaw, D.A. Hood, The effectof training on the expression of mitochondrial biogenesis- and apoptosis-related pro-teins in skeletal muscle of patients with mtDNA defects, Am. J. Physiol. Endocrinol.Metab. 293 (2007) E672–E680.
[258] J.P. Morton, D.P. Maclaren, N.T. Cable, I.T. Campbell, L. Evans, A.C. Kayani,A. McArdle, B. Drust, Trained men display increased basal heat shock protein contentof skeletal muscle, Med. Sci. Sports Exerc. 40 (2008) 1255–1262.
[259] N. Ferrara, B. Rinaldi, G. Corbi, V. Conti, P. Stiuso, S. Boccuti, G. Rengo, F. Rossi,A. Filippelli, Exercise training promotes SIRT1 activity in aged rats, RejuvenationRes. 11 (2008) 139–150.
[260] J.M. Lawler, H.B. Kwak, J.H. Kim, M.H. Suk, Exercise training inducibility ofMnSOD protein expression and activity is retained while reducing prooxidant signal-ing in the heart of senescent rats, Am. J. Physiol. Regul. Integr. Comp. Physiol.296 (2009) R1496–R1502.
[261] X. Xu, W. Zhao, W. Wan, L.L. Ji, A.S. Powers, J.M. Erikson, J.Q. Zhang, Exercisetraining combined with angiotensin II receptor blockade reduces oxidative stress aftermyocardial infarction in rats, Exp. Physiol. 95 (2010) 1008–1015.
[262] D. Garcia-Lopez, K. Hakkinen, M.J. Cuevas, E. Lima, A. Kauhanen, M. Mattila,E. Sillanpaa, J.P. Ahtiainen, L. Karavirta, M. Almar, J. Gonzalez-Gallego, Effects ofstrength and endurance training on antioxidant enzyme gene expression and activityin middle-aged men, Scand. J. Med. Sci. Sports 17 (2007) 595–604.
[263] H. Bo, N. Jiang, G. Ma, J. Qu, G. Zhang, D. Cao, L. Wen, S. Liu, L.L. Ji, Y. Zhang,Regulation of mitochondrial uncoupling respiration during exercise in rat heart: roleof reactive oxygen species (ROS) and uncoupling protein 2, Free Radic. Biol. Med.44 (2008) 1373–1381.
[264] N. Spurway, H. Wackerhage, Genetics and Molecular Biology of Muscle Adaptation,first ed., Churchill Livingstone, Edinburgh, 2006.
[265] H.E.Montgomery, P. Clarkson, C.M. Dollery, K. Prasad, M.A. Losi, H. Hemingway,D. Statters, M. Jubb, M. Girvain, A. Varnava, M. World, J. Deanfield, P. Talmud,
129Manganese Superoxide Dismutase and Oxidative Stress Modulation
Author's personal copy
J.R. McEwan, W.J. McKenna, S. Humphries, Association of angiotensin-convertingenzyme gene I/D polymorphism with change in left ventricular mass in response tophysical training, Circulation 96 (1997) 741–747.
[266] Z. Puthucheary, J.R. Skipworth, J. Rawal, M. Loosemore, K. Van Someren,H.E. Montgomery, The ACE gene and human performance: 12 years on, SportsMed. 41 (2011) 433–448.
[267] M. Collins, G.G.Mokone, A.V. September, L. van derMerwe,M.P. Schwellnus, TheCOL5A1 genotype is associated with range of motion measurements, Scand. J. Med.Sci. Sports 19 (2009) 803–810.
[268] M. Posthumus, M.P. Schwellnus, M. Collins, The COL5A1 gene: a novel marker ofendurance running performance, Med. Sci. Sports Exerc. 43 (2011) 584–589.
[269] K. O’Connell, M. Posthumus, M. Collins, COL6A1 gene and Ironman triathlon per-formance, Int. J. Sports Med. 32 (2011) 896–901.
[270] A. Lucia, F. Gomez-Gallego, C. Santiago, F. Bandres, C. Earnest, M. Rabadan,J.M. Alonso, J. Hoyos, A. Cordova, G. Villa, C. Foster, ACTN3 genotype in profes-sional endurance cyclists, Int. J. Sports Med. 27 (2006) 880–884.
[271] C. Fiuza-Luces, J.R. Ruiz, G. Rodriguez-Romo, C. Santiago, F. Gomez-Gallego,T. Yvert, A. Cano-Nieto, N. Garatachea, M. Moran, A. Lucia, Are ‘endurance’ alleles‘survival’ alleles? Insights from the ACTN3 R577X polymorphism, PLoS One6 (2011) e17558.
[272] C. Bouchard, Genomic predictors of trainability, Exp. Physiol. 97 (2012) 347–352.[273] A.K. Akimoto, A.L.Miranda-Vilela, P.C. Alves, L.C. Pereira, G.S. Lordelo, O. Hiragi
Cde, I.C. da Silva, C.K. Grisolia, N. Klautau-Guimaraes Mde, Evaluation of genepolymorphisms in exercise-induced oxidative stress and damage, Free Radic. Res.44 (2010) 322–331.
[274] I.I. Ahmetov, V.A. Naumov, A.E. Donnikov, A. Maciejewska-Karłowska,E.S. Kostryukova, A.K. Larin, E.V. Maykova, D.G. Alexeev, O.N. Fedotovskaya,E.V. Generozov, Z. Jastrzebski, P. Zmijewski, O.A. Kravtsova, N.A. Kulemin,A. Leonska-Duniec, D.S. Martykanova, E.A. Ospanova, A.V. Pavlenko,A.A. Podol’skaya, M. Sawczuk, F.K. Alimova, D.Y. Trofimov, V.M. Govorun,P. Cieszczyk, SOD2 gene polymorphism and muscle damage markers in elite athletes,Free Radic. Res. 48 (2014) 948–955.
[275] G. Bresciani, J. Gonzalez-Gallego, I.B. da Cruz, J.A. de Paz, M.J. Cuevas, TheAla16Val MnSOD gene polymorphism modulates oxidative response to exercise,Clin. Biochem. 46 (2013) 335–340.
[276] A.L. Miranda-Vilela, A.K. Akimoto, P.C. Alves, L.C. Pereira, C.A. Goncalves,M.N. Klautau-Guimaraes, C.K. Grisolia, Dietary carotenoid-rich pequi oil reducesplasma lipid peroxidation and DNA damage in runners and evidence for an associationwith MnSOD genetic variant -Val9Ala, Genet. Mol. Res. 8 (2009) 1481–1495.
[277] A.L. Miranda-Vilela, P.C. Alves, A.K. Akimoto, L.C. Pereira, M. Nazare Klautau-Guimaraes, C.K. Grisolia, The effect of hydrogen peroxide-induced oxidative stresson leukocytes depends on age and physical training in healthy human subjects carryingthe same genotypes of antioxidant enzymes’ gene polymorphisms, Am. J. Hum. Biol.22 (2010) 807–812.
130 Guilherme Bresciani et al.
Author's personal copy